array:24 [
  "pii" => "S0001731024006549"
  "issn" => "00017310"
  "doi" => "10.1016/j.ad.2024.02.036"
  "estado" => "S300"
  "fechaPublicacion" => "2024-10-01"
  "aid" => "4048"
  "copyright" => "AEDV"
  "copyrightAnyo" => "2024"
  "documento" => "simple-article"
  "crossmark" => 1
  "subdocumento" => "crp"
  "cita" => "Actas Dermosifiliogr. 2024;115:T906-T911"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:1 [
    "total" => 0
  ]
  "itemSiguiente" => array:18 [
    "pii" => "S0001731024000425"
    "issn" => "00017310"
    "doi" => "10.1016/j.ad.2023.03.015"
    "estado" => "S300"
    "fechaPublicacion" => "2024-10-01"
    "aid" => "3804"
    "copyright" => "AEDV"
    "documento" => "simple-article"
    "crossmark" => 1
    "subdocumento" => "crp"
    "cita" => "Actas Dermosifiliogr. 2024;115:913-4"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:1 [
      "total" => 0
    ]
    "es" => array:11 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">CASOS PARA EL DIAGN&#211;STICO</span>"
      "titulo" => "N&#243;dulo eritematoso en labio superior"
      "tienePdf" => "es"
      "tieneTextoCompleto" => "es"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "913"
          "paginaFinal" => "914"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "en" => array:1 [
          "titulo" => "Erythematous nodule on the upper lip"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "es" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:7 [
          "identificador" => "fig0010"
          "etiqueta" => "Figura 2"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "gr2.jpeg"
              "Alto" => 621
              "Ancho" => 930
              "Tamanyo" => 215698
            ]
          ]
          "descripcion" => array:1 [
            "es" => "<p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Proliferaci&#243;n intrad&#233;rmica de estructuras vasculares lobuladas con endotelio prominente e infiltrado inflamatorio &#40;panor&#225;mica Hematoxilina&#38;Eosina&#41; &#40;A&#41;&#46; C&#233;lulas endoteliales prominentes con abundante citoplasma eosin&#243;filo &#40;H&#38;E x10&#41; &#40;B&#41;&#46; C&#233;lulas endoteliales prominentes con abundante citoplasma eosin&#243;filo rodeadas principalmente de linfocitos y algunos eosin&#243;filos aislados &#40;H&#38;E x20&#41; &#40;C&#41; Resoluci&#243;n completa de los n&#243;dulos eritematosos tras tratamiento con l&#225;ser&#46;</p>"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "M&#46;D&#46; Pegalajar-Garc&#237;a, I&#46; P&#233;rez-L&#243;pez, F&#46;J&#46; Navarro-Trivi&#241;o"
          "autores" => array:3 [
            0 => array:2 [
              "nombre" => "M&#46;D&#46;"
              "apellidos" => "Pegalajar-Garc&#237;a"
            ]
            1 => array:2 [
              "nombre" => "I&#46;"
              "apellidos" => "P&#233;rez-L&#243;pez"
            ]
            2 => array:2 [
              "nombre" => "F&#46;J&#46;"
              "apellidos" => "Navarro-Trivi&#241;o"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731024000425?idApp=UINPBA000044"
    "url" => "/00017310/0000011500000009/v2_202410160548/S0001731024000425/v2_202410160548/es/main.assets"
  ]
  "itemAnterior" => array:18 [
    "pii" => "S0001731024004150"
    "issn" => "00017310"
    "doi" => "10.1016/j.ad.2024.02.033"
    "estado" => "S300"
    "fechaPublicacion" => "2024-10-01"
    "aid" => "3955"
    "copyright" => "AEDV"
    "documento" => "simple-article"
    "crossmark" => 1
    "subdocumento" => "crp"
    "cita" => "Actas Dermosifiliogr. 2024;115:906-11"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:1 [
      "total" => 0
    ]
    "es" => array:14 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Comunicaci&#243;n Breve</span>"
      "titulo" => "Estudio del impacto de las restricciones en el acceso a f&#225;rmacos biol&#243;gicos en psoriasis sobre la actividad m&#237;nima de la enfermedad&#58; suban&#225;lisis de los proyectos EQUIDAD y AME de la AEDV"
      "tienePdf" => "es"
      "tieneTextoCompleto" => "es"
      "tieneResumen" => array:3 [
        0 => "es"
        1 => "es"
        2 => "en"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "906"
          "paginaFinal" => "911"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "en" => array:1 [
          "titulo" => "Study of the Impact of Restrictions on Access to Biological Drugs for the Management of Psoriasis on the Minimum Disease Activity Criteria&#58; Subanalysis of AEDV EQUIDAD and AME Projects"
        ]
      ]
      "contieneResumen" => array:2 [
        "es" => true
        "en" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "es" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 1
        "multimedia" => array:5 [
          "identificador" => "fig0010"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => false
          "mostrarDisplay" => true
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "fx1.jpeg"
              "Alto" => 886
              "Ancho" => 1340
              "Tamanyo" => 171271
            ]
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "M&#46; S&#225;nchez-D&#237;az, &#193;&#46; Fl&#243;rez, G&#46; Carretero-Hern&#225;ndez, M&#46; Grau-P&#233;rez, I&#46; Garc&#237;a-Doval, J&#46;M&#46; Carrascosa-Carrillo"
          "autores" => array:6 [
            0 => array:2 [
              "nombre" => "M&#46;"
              "apellidos" => "S&#225;nchez-D&#237;az"
            ]
            1 => array:2 [
              "nombre" => "&#193;&#46;"
              "apellidos" => "Fl&#243;rez"
            ]
            2 => array:2 [
              "nombre" => "G&#46;"
              "apellidos" => "Carretero-Hern&#225;ndez"
            ]
            3 => array:2 [
              "nombre" => "M&#46;"
              "apellidos" => "Grau-P&#233;rez"
            ]
            4 => array:2 [
              "nombre" => "I&#46;"
              "apellidos" => "Garc&#237;a-Doval"
            ]
            5 => array:2 [
              "nombre" => "J&#46;M&#46;"
              "apellidos" => "Carrascosa-Carrillo"
            ]
          ]
        ]
      ]
      "resumen" => array:1 [
        0 => array:3 [
          "titulo" => "Graphical abstract"
          "clase" => "graphical"
          "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall"><elsevierMultimedia ident="fig0010"></elsevierMultimedia></p></span>"
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731024004150?idApp=UINPBA000044"
    "url" => "/00017310/0000011500000009/v2_202410160548/S0001731024004150/v2_202410160548/es/main.assets"
  ]
  "asociados" => array:1 [
    0 => array:18 [
      "pii" => "S0001731024004150"
      "issn" => "00017310"
      "doi" => "10.1016/j.ad.2024.02.033"
      "estado" => "S300"
      "fechaPublicacion" => "2024-10-01"
      "aid" => "3955"
      "copyright" => "AEDV"
      "documento" => "simple-article"
      "crossmark" => 1
      "subdocumento" => "crp"
      "cita" => "Actas Dermosifiliogr. 2024;115:906-11"
      "abierto" => array:3 [
        "ES" => true
        "ES2" => true
        "LATM" => true
      ]
      "gratuito" => true
      "lecturas" => array:1 [
        "total" => 0
      ]
      "es" => array:14 [
        "idiomaDefecto" => true
        "cabecera" => "<span class="elsevierStyleTextfn">Comunicaci&#243;n Breve</span>"
        "titulo" => "Estudio del impacto de las restricciones en el acceso a f&#225;rmacos biol&#243;gicos en psoriasis sobre la actividad m&#237;nima de la enfermedad&#58; suban&#225;lisis de los proyectos EQUIDAD y AME de la AEDV"
        "tienePdf" => "es"
        "tieneTextoCompleto" => "es"
        "tieneResumen" => array:3 [
          0 => "es"
          1 => "es"
          2 => "en"
        ]
        "paginas" => array:1 [
          0 => array:2 [
            "paginaInicial" => "906"
            "paginaFinal" => "911"
          ]
        ]
        "titulosAlternativos" => array:1 [
          "en" => array:1 [
            "titulo" => "Study of the Impact of Restrictions on Access to Biological Drugs for the Management of Psoriasis on the Minimum Disease Activity Criteria&#58; Subanalysis of AEDV EQUIDAD and AME Projects"
          ]
        ]
        "contieneResumen" => array:2 [
          "es" => true
          "en" => true
        ]
        "contieneTextoCompleto" => array:1 [
          "es" => true
        ]
        "contienePdf" => array:1 [
          "es" => true
        ]
        "resumenGrafico" => array:2 [
          "original" => 1
          "multimedia" => array:5 [
            "identificador" => "fig0010"
            "tipo" => "MULTIMEDIAFIGURA"
            "mostrarFloat" => false
            "mostrarDisplay" => true
            "figura" => array:1 [
              0 => array:4 [
                "imagen" => "fx1.jpeg"
                "Alto" => 886
                "Ancho" => 1340
                "Tamanyo" => 171271
              ]
            ]
          ]
        ]
        "autores" => array:1 [
          0 => array:2 [
            "autoresLista" => "M&#46; S&#225;nchez-D&#237;az, &#193;&#46; Fl&#243;rez, G&#46; Carretero-Hern&#225;ndez, M&#46; Grau-P&#233;rez, I&#46; Garc&#237;a-Doval, J&#46;M&#46; Carrascosa-Carrillo"
            "autores" => array:6 [
              0 => array:2 [
                "nombre" => "M&#46;"
                "apellidos" => "S&#225;nchez-D&#237;az"
              ]
              1 => array:2 [
                "nombre" => "&#193;&#46;"
                "apellidos" => "Fl&#243;rez"
              ]
              2 => array:2 [
                "nombre" => "G&#46;"
                "apellidos" => "Carretero-Hern&#225;ndez"
              ]
              3 => array:2 [
                "nombre" => "M&#46;"
                "apellidos" => "Grau-P&#233;rez"
              ]
              4 => array:2 [
                "nombre" => "I&#46;"
                "apellidos" => "Garc&#237;a-Doval"
              ]
              5 => array:2 [
                "nombre" => "J&#46;M&#46;"
                "apellidos" => "Carrascosa-Carrillo"
              ]
            ]
          ]
        ]
        "resumen" => array:1 [
          0 => array:3 [
            "titulo" => "Graphical abstract"
            "clase" => "graphical"
            "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall"><elsevierMultimedia ident="fig0010"></elsevierMultimedia></p></span>"
          ]
        ]
      ]
      "idiomaDefecto" => "es"
      "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731024004150?idApp=UINPBA000044"
      "url" => "/00017310/0000011500000009/v2_202410160548/S0001731024004150/v2_202410160548/es/main.assets"
    ]
  ]
  "en" => array:21 [
    "idiomaDefecto" => true
    "cabecera" => "<span class="elsevierStyleTextfn">Brief Comunication</span>"
    "titulo" => " Study of the Impact of Restrictions on Access to Biological Drugs for the Management of Psoriasis on the Minimum Disease Activity Criteria&#58; Subanalysis of AEDV EQUIDAD and AME Projects"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "T906"
        "paginaFinal" => "T911"
      ]
    ]
    "autores" => array:1 [
      0 => array:4 [
        "autoresLista" => "M&#46; S&#225;nchez-D&#237;az, &#193;&#46; Fl&#243;rez, G&#46; Carretero-Hern&#225;ndez, M&#46; Grau-P&#233;rez, I&#46; Garc&#237;a-Doval, J&#46;M&#46; Carrascosa-Carrillo"
        "autores" => array:6 [
          0 => array:3 [
            "nombre" => "M&#46;"
            "apellidos" => "S&#225;nchez-D&#237;az"
            "referencia" => array:2 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
            ]
          ]
          1 => array:3 [
            "nombre" => "&#193;&#46;"
            "apellidos" => "Fl&#243;rez"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">c</span>"
                "identificador" => "aff0015"
              ]
            ]
          ]
          2 => array:3 [
            "nombre" => "G&#46;"
            "apellidos" => "Carretero-Hern&#225;ndez"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">d</span>"
                "identificador" => "aff0020"
              ]
            ]
          ]
          3 => array:3 [
            "nombre" => "M&#46;"
            "apellidos" => "Grau-P&#233;rez"
            "referencia" => array:2 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">e</span>"
                "identificador" => "aff0025"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">f</span>"
                "identificador" => "aff0030"
              ]
            ]
          ]
          4 => array:4 [
            "nombre" => "I&#46;"
            "apellidos" => "Garc&#237;a-Doval"
            "email" => array:1 [
              0 => "ignacio.garcia.doval@sergas.es"
            ]
            "referencia" => array:3 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">f</span>"
                "identificador" => "aff0030"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">g</span>"
                "identificador" => "aff0035"
              ]
              2 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">&#42;</span>"
                "identificador" => "cor0005"
              ]
            ]
          ]
          5 => array:3 [
            "nombre" => "J&#46;M&#46;"
            "apellidos" => "Carrascosa-Carrillo"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">h</span>"
                "identificador" => "aff0040"
              ]
            ]
          ]
        ]
        "afiliaciones" => array:8 [
          0 => array:3 [
            "entidad" => "Unidad de Investigaci&#243;n&#44; Fundaci&#243;n Piel Sana de la Academia Espa&#241;ola de Dermatolog&#237;a y Venereolog&#237;a&#44; Madrid&#44; Spain"
            "etiqueta" => "a"
            "identificador" => "aff0005"
          ]
          1 => array:3 [
            "entidad" => "Servicio de Dermatolog&#237;a&#44; Hospital Universitario Virgen de las Nieves Instituto de Investigaci&#243;n Biosanitaria IBS&#44; Granada&#44; Spain"
            "etiqueta" => "b"
            "identificador" => "aff0010"
          ]
          2 => array:3 [
            "entidad" => "Servicio de Dermatolog&#237;a&#44; Complejo Hospitalario Universitario de Pontevedra&#44; Grupo de Investigaci&#243;n DIPO&#44; IIS Galicia Sur-SERGAS-UVIGO&#44; Pontevedra&#44; Spain"
            "etiqueta" => "c"
            "identificador" => "aff0015"
          ]
          3 => array:3 [
            "entidad" => "Servicio de Dermatolog&#237;a&#44; Hospital Universitario de Gran Canaria Doctor Negr&#237;n&#44; Las Palmas de Gran Canaria&#44; Isla de Gran Canaria&#44; Spain"
            "etiqueta" => "d"
            "identificador" => "aff0020"
          ]
          4 => array:3 [
            "entidad" => "Servicio de Dermatolog&#237;a&#44; Hospital Universitario Puerta de Hierro-Majadahonda&#44; Majadahonda&#44; Madrid&#44; Spain"
            "etiqueta" => "e"
            "identificador" => "aff0025"
          ]
          5 => array:3 [
            "entidad" => "Unidad de Investigaci&#243;n&#44; Fundaci&#243;n Piel Sana de la Academia Espa&#241;ola de Dermatolog&#237;a y Venereolog&#237;a&#44; Madrid&#44; Spain"
            "etiqueta" => "f"
            "identificador" => "aff0030"
          ]
          6 => array:3 [
            "entidad" => "Servicio de Dermatolog&#237;a&#44; Hospital do Meixoeiro&#44; Vigo&#44; Pontevedra&#44; Spain"
            "etiqueta" => "g"
            "identificador" => "aff0035"
          ]
          7 => array:3 [
            "entidad" => "Servicio de Dermatolog&#237;a&#44; Hospital Universitario Germans Trias i Pujol&#44; Badalona&#44; Barcelona&#44; Spain"
            "etiqueta" => "h"
            "identificador" => "aff0040"
          ]
        ]
        "correspondencia" => array:1 [
          0 => array:3 [
            "identificador" => "cor0005"
            "etiqueta" => "&#8270;"
            "correspondencia" => "Corresponding author&#46;"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "es" => array:1 [
        "titulo" => "Estudio del impacto de las restricciones en el acceso a f&#225;rmacos biol&#243;gicos en psoriasis sobre la actividad m&#237;nima de la enfermedad&#58; suban&#225;lisis de los proyectos EQUIDAD y AME de la AEDV"
      ]
    ]
    "resumenGrafico" => array:2 [
      "original" => 1
      "multimedia" => array:5 [
        "identificador" => "fig0010"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => false
        "mostrarDisplay" => true
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "fx1.jpeg"
            "Alto" => 886
            "Ancho" => 1385
            "Tamanyo" => 161205
          ]
        ]
      ]
    ]
    "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0030">Introduction</span><p id="par0005" class="elsevierStylePara elsevierViewall">The development of biological drugs has represented a paradigm shift in the management of psoriasis&#44; allowing for long-term disease control with a good safety profile<a class="elsevierStyleCrossRefs" href="#bib0050"><span class="elsevierStyleSup">1&#44;2</span></a>&#46; However&#44; their use can have a significant economic impact on the Spanish National Health System<a class="elsevierStyleCrossRef" href="#bib0060"><span class="elsevierStyleSup">3</span></a> &#40;NHS&#41;&#46;</p><p id="par0010" class="elsevierStylePara elsevierViewall">Because of the specific characteristics of the Spanish NHS&#44; each autonomous community &#40;AC&#41; manages the health services of its territory and can decide on the conditions and requirements to prescribe drugs<a class="elsevierStyleCrossRefs" href="#bib0060"><span class="elsevierStyleSup">3&#44;4</span></a>&#46; In the cross-sectional EQUIDAD study&#44; a situation of disparities in the conditions of access to biological drugs for psoriasis among different ACs was observed&#44; with diversity in criteria at both regional and local levels&#46; The criteria did not appear to be based on decision-making methods that demonstrate the integration of scientific evidence<a class="elsevierStyleCrossRef" href="#bib0070"><span class="elsevierStyleSup">5</span></a>&#46;</p><p id="par0015" class="elsevierStylePara elsevierViewall">Independently&#44; the Spanish Academy of Dermatology and Venereology Psoriasis Working Group &#40;AEDV PWG&#41; developed the minimal disease activity &#40;MDA&#41; variable for the management of psoriasis<a class="elsevierStyleCrossRef" href="#bib0075"><span class="elsevierStyleSup">6</span></a>&#44; with the intent of using it as a measure of adequate disease management by characterizing patients with well-controlled psoriasis&#46; After it was defined&#44; a study was conducted at the end of 2022 to describe the situation of MDA&#44; evaluating the percentage of psoriatic patients who meet the MDA criteria in a routine clinical practice in Spain &#40;reference for MDA study&#41;&#46;</p><p id="par0020" class="elsevierStylePara elsevierViewall">The objective of the present study was to investigate the association between the probabilities of achieving MDA and the restrictions observed in access to new drugs in the treatment of psoriasis at both regional and local levels&#44; combining data from the independent EQUIDAD and MDA trials of the AEDV&#46;</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0035">Materials and methods</span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0040">Data source</span><p id="par0025" class="elsevierStylePara elsevierViewall">Data from 2 independent cross-sectional studies were combined&#58; the EQUIDAD<a class="elsevierStyleCrossRef" href="#bib0070"><span class="elsevierStyleSup">5</span></a> study conducted by the AEDV&#44; and the MDA &#40;reference&#41; study conducted by the AEDV PWG&#46; Briefly&#44; data for the EQUIDAD study were collected through an online questionnaire in March 2023&#44; which evaluated the existing regional and local prescription conditions in each AC from an ecological perspective&#46; The EQUIDAD study asked 2 dermatologists with management duties in each AC and only included restrictions reflected in official documents&#46; Data for the MDA study were collected from July through November 2022 via consecutive sampling of patients from psoriasis units from various geographic areas covering almost all provinces of Spain&#46;</p></span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0045">Drugs evaluated in the study</span><p id="par0030" class="elsevierStylePara elsevierViewall">New therapeutic targets for biological drugs for the treatment psoriasis were included&#44; for which funding resolutions were issued in the therapeutic positioning index &#40;TPI&#41; from 2016 through 2022 &#40;ixekizumab&#44; brodalumab&#44; guselkumab&#44; tildrakizumab&#44; risankizumab&#44; and bimekizumab&#41;&#46;</p></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0050">Variables of interest</span><p id="par0035" class="elsevierStylePara elsevierViewall">The following variables were collected&#58;<ul class="elsevierStyleList" id="lis0005"><li class="elsevierStyleListItem" id="lsti0005"><span class="elsevierStyleLabel">a&#41;</span><p id="par0040" class="elsevierStylePara elsevierViewall">Compliance with MDA&#58; MDA was defined as the absence of active arthritis plus 3 of the following 6 characteristics&#58; itch &#8804; 1&#47;10&#59; scaling &#8804; 2&#47;10&#59; redness &#8804; 2&#47;10&#59; visibility &#8804; 2&#47;10&#59; body surface area affected &#8804; 2&#37;&#59; Dermatology Life Quality Index &#40;DLQI&#41; scores &#8804; 2&#59; and absence of lesions in special locations<a class="elsevierStyleCrossRef" href="#bib0075"><span class="elsevierStyleSup">6</span></a>&#46;</p></li><li class="elsevierStyleListItem" id="lsti0010"><span class="elsevierStyleLabel">b&#41;</span><p id="par0045" class="elsevierStylePara elsevierViewall">Conditions for prescription in each AC&#58; For patients in each AC&#44; the level of restrictions greater than those required by the TPI at both regional and local levels for the prescription of the evaluated drugs was categorically recorded&#46;</p></li><li class="elsevierStyleListItem" id="lsti0015"><span class="elsevierStyleLabel">c&#41;</span><p id="par0050" class="elsevierStylePara elsevierViewall">Other variables&#58; Other variables from the MDA study were collected for each patient&#44; such as sex&#44; age&#44; use of biological drugs&#44; and AC of the treating hospital&#46;</p></li></ul></p></span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0055">Statistical analysis</span><p id="par0055" class="elsevierStylePara elsevierViewall">Qualitative variables were expressed as distributions of relative and absolute frequencies&#46; Quantitative variables were expressed as mean and standard deviation&#46; The probability of meeting the MDA criteria based on the level of regional and local restrictions described for each AC was analyzed using a crude multilevel logistic regression model&#44; along with yet another model adjusted for possible confounders such as age&#44; sex&#44; or current use of biological drugs&#46; A total of 3 sensitivity analyses were performed by regrouping the &#8220;level of restrictions&#8221; variable into different categories&#44; which eventually led to a dichotomous model &#40;less restrictive vs more restrictive ACs&#41;&#46; Statistical significance was considered for p-values &#60;<span class="elsevierStyleHsp" style=""></span>0&#46;05&#46; All analyses were performed with STATA&#174; &#40;Stata Corp&#46; 2021&#46; Stata Statistical Software&#58; version 17&#41;&#46;</p></span></span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0060">Results</span><p id="par0060" class="elsevierStylePara elsevierViewall">In the MDA study&#44; a final sample of 830 patients was obtained&#44; although only 825 were considered for this work&#44; representing a total of 17 different ACs &#40;5 patients did not have their region on record&#41;&#46; The mean age was 51&#46;4 years &#40;SD&#44; 14&#46;2&#41; and 49&#46;6&#37; were on biological therapy&#46; The MDA criteria were met in 40&#46;8&#37; of the patients included in the study&#46; A total of 62&#46;4&#37; of patients are still being followed in 9 ACs without regional restrictions &#40;although local restrictions may exist&#41;&#46; Combining the MDA data with the levels of restrictions in the ACs based on the EQUIDAD study<a class="elsevierStyleCrossRef" href="#bib0070"><span class="elsevierStyleSup">5</span></a>&#44; a trend can be seen&#44; with 28&#46;4&#37; of patients with MDA in the 3 most restrictive ACs vs 50&#46;7&#37; of MDA in the 7 least restrictive ACs&#44; with statistically significant differences &#40;p &#60;<span class="elsevierStyleHsp" style=""></span>0&#46;001&#41; &#40;<a class="elsevierStyleCrossRef" href="#fig0005">fig&#46; 1</a>&#41;&#46; The distribution of patients in the different AC groups based on the level of restrictions&#44; as well as the characteristics of these groups are shown in <a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>&#46;</p><elsevierMultimedia ident="fig0005"></elsevierMultimedia><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><p id="par0065" class="elsevierStylePara elsevierViewall">In the crude multilevel logistic model &#40;<a class="elsevierStyleCrossRef" href="#sec0050">Supplementary data Table 1</a>&#41;&#44; this gradient of probability of achieving MDA was replicated at the same time the level of restrictions decreased&#46; Being treated in an AC without regional restrictions &#40;although local ones may exist&#41; was independently associated with a higher probability of meeting the MDA criteria &#40;OR&#44; 2&#46;39&#59; 95&#37;CI&#44; 1&#46;04-5&#46;51&#41;&#46; Although adjustment for the use of biological drugs &#40;<a class="elsevierStyleCrossRef" href="#sec0050">Supplementary data Table 1</a>&#44; adjusted model&#41; showed a clear association with achieving MDA &#40;OR&#44; 5&#46;86&#59; 95&#37;CI&#44; 4&#46;18-8&#46;23&#41;&#44; it did not eliminate the effect of geographical restrictions &#40;OR&#44; 2&#46;64&#59; 95&#37;CI&#44; 1&#46;08-6&#46;42&#41;&#46; The model that categorized restrictions ordinally also showed a gradient of probability of achieving MDA as the level of restrictions dropped &#40;OR&#44; 1&#46;27&#59; 95&#37;CI&#44; 1&#46;06-1&#46;52&#59; p<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#46;011&#41;&#46;</p><p id="par0070" class="elsevierStylePara elsevierViewall">As sensitivity analysis&#44; the variable with the level of restrictions was regrouped into fewer categories&#44; finding similar results in all cases &#40;data not shown&#41;&#46; The graphic representation of the percentage of MDA found in each AC and its level of restrictions is shown in <a class="elsevierStyleCrossRef" href="#fig0005">Figure 1</a>&#46;</p></span><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0065">Discussion</span><p id="par0075" class="elsevierStylePara elsevierViewall">The presence of fewer restrictions&#44; both local and regional&#44; in access to new drugs for psoriasis seems to be associated with a higher probability of meeting the MDA criteria and&#44; therefore&#44; achieving adequate control of psoriatic disease&#46; This association is independent of other factors&#44; such as age or sex&#44; and is maintained when including the use of biological drugs by the patient in the model&#46;</p><p id="par0080" class="elsevierStylePara elsevierViewall">The relationship found between controlling psoriatic disease and other factors such as the use of biological drugs or socio-economic level are factors already evaluated previously<a class="elsevierStyleCrossRefs" href="#bib0080"><span class="elsevierStyleSup">7&#44;8</span></a>&#46; However&#44; few studies have evaluated the impact of drug access-related restrictions on the control of psoriasis&#44; focusing on comparisons across different countries<a class="elsevierStyleCrossRef" href="#bib0090"><span class="elsevierStyleSup">9</span></a>&#46; The differences between ACs reported in this study are more relevant as they are differences within the same country where equitable health care for all patients is presumed&#46;</p><p id="par0085" class="elsevierStylePara elsevierViewall">It seems logical to think that the absence of specific restrictions could favor the prescription of drugs based on clinical needs&#44; without being conditioned by financial or organizational factors&#46; The fact that the relationship between restrictions and MDA is maintained when including the binary variable &#8220;biologicals&#8221; in the model raises the possibility that the ease of access to new drugs does not fully explain the better disease control in areas with fewer restrictions&#46; Therefore&#44; persistent differences could be due to reasons other than treatment with new drugs &#40;which are also associated with the number of restrictions&#41;&#44; or to the possibility of selecting specific new drugs that are more effective based on national or international recommendations<a class="elsevierStyleCrossRef" href="#bib0055"><span class="elsevierStyleSup">2</span></a>&#46;</p><p id="par0090" class="elsevierStylePara elsevierViewall">An alternative explanation is that access to a dermatologist may be easier in ACs with fewer restrictions&#44; finding a higher proportion of patients with milder psoriasis who would more likely meet MDA criteria&#46;</p><p id="par0095" class="elsevierStylePara elsevierViewall">The strength of this study is that it is based on data from independent studies conducted before generating the hypothesis&#44; which makes it unlikely that MDA measurements could be biased by the description of local restrictions&#46; As for the limitations&#44; the main one is that it is an ecological study&#44; meaning that data on limitations are collected at AC level and the patients in whom MDA was measured may not be the same as those who experienced limitations in drug use&#46; It is also possible that restrictions allow the total number of prescriptions in the AC to be higher and&#44; although the benefit for each patient is smaller&#44; the overall benefit for the population is higher&#46; On the other hand&#44; the use of consecutive sampling may not be equally representative of the population of psoriatic patients in all ACs&#46; Additionally&#44; evaluating restrictions from a regional perspective probably does not accurately reflect the specific restrictions existing at each hospital level&#46;</p><p id="par0100" class="elsevierStylePara elsevierViewall">In conclusion&#44; the observed findings suggest that there is a relationship between a lower level of restrictions on access to biological drugs and a higher probability of adequate control of psoriatic disease&#46; It would be desirable to homogenize the prescription criteria among the different Spanish ACs to promote greater equity in the treatment of psoriasis nationwide</p></span><span id="sec0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0070">Conflicts of interest</span><p id="par0105" class="elsevierStylePara elsevierViewall">Manuel S&#225;nchez D&#237;az has received funding for attending conferences from Sanofi&#44; Lilly&#44; Novartis&#44; and Almirall&#46;</p><p id="par0110" class="elsevierStylePara elsevierViewall">&#193;ngeles Fl&#243;rez has received fees and&#47;or support for educational activities and&#47;or acted as a speaker and&#47;or consultant and&#47;or conducted clinical trials and&#47;or research projects for Abbvie&#44; ACELYRIN Inc&#44; Alcedis GmbH&#44; Almirall&#44; Amgen&#44; BMS&#44; Celgene&#44; Galderma&#44; Incyte Corporation&#44; Janssen-Cilag&#44; Kyowa Kirin&#44; Leo Pharma&#44; Lilly&#44; Novartis&#44; Pfizer&#44; Roche Farma&#44; Sanofi-Aventis&#44; Sun Pharma&#44; Takeda&#44; and UCB Biosciences GmbH&#46;</p><p id="par0115" class="elsevierStylePara elsevierViewall">Merc&#232; Grau-P&#233;rez has received funding for attending courses or conferences from Abbvie&#44; Almirall&#44; Janssen&#44; Lilly&#44; and Novartis&#46;</p><p id="par0120" class="elsevierStylePara elsevierViewall">Ignacio Garc&#237;a-Doval has received funding for attending conferences from Abbvie&#44; MSD&#44; Pfizer&#44; and Sanofi&#46;</p><p id="par0125" class="elsevierStylePara elsevierViewall">Jos&#233;-Manuel Carrascosa has received fees and&#47;or support for educational activities and&#47;or acted as a speaker and&#47;or consultant and&#47;or conducted clinical trials and&#47;or research projects for Abbvie&#44; Almirall&#44; Amgen&#44; BMS&#44; Celgene&#44; Galderma&#44; Janssen-Cilag&#44; Leo Pharma&#44; Lilly&#44; Novartis&#44; Pfizer&#44; Sanofi-Aventis&#44; UCB&#44; Sandoz&#44; and Boehringer Ingelheim&#46;</p></span></span>"
    "textoCompletoSecciones" => array:1 [
      "secciones" => array:12 [
        0 => array:3 [
          "identificador" => "xres2271948"
          "titulo" => "Graphical abstract"
          "secciones" => array:1 [
            0 => array:1 [
              "identificador" => "abst0005"
            ]
          ]
        ]
        1 => array:3 [
          "identificador" => "xres2271950"
          "titulo" => "Abstract"
          "secciones" => array:1 [
            0 => array:1 [
              "identificador" => "abst0010"
            ]
          ]
        ]
        2 => array:2 [
          "identificador" => "xpalclavsec1893690"
          "titulo" => "Keywords"
        ]
        3 => array:3 [
          "identificador" => "xres2271949"
          "titulo" => "Resumen"
          "secciones" => array:1 [
            0 => array:1 [
              "identificador" => "abst0015"
            ]
          ]
        ]
        4 => array:2 [
          "identificador" => "xpalclavsec1893691"
          "titulo" => "Palabras clave"
        ]
        5 => array:2 [
          "identificador" => "sec0005"
          "titulo" => "Introduction"
        ]
        6 => array:3 [
          "identificador" => "sec0010"
          "titulo" => "Materials and methods"
          "secciones" => array:4 [
            0 => array:2 [
              "identificador" => "sec0015"
              "titulo" => "Data source"
            ]
            1 => array:2 [
              "identificador" => "sec0020"
              "titulo" => "Drugs evaluated in the study"
            ]
            2 => array:2 [
              "identificador" => "sec0025"
              "titulo" => "Variables of interest"
            ]
            3 => array:2 [
              "identificador" => "sec0030"
              "titulo" => "Statistical analysis"
            ]
          ]
        ]
        7 => array:2 [
          "identificador" => "sec0035"
          "titulo" => "Results"
        ]
        8 => array:2 [
          "identificador" => "sec0040"
          "titulo" => "Discussion"
        ]
        9 => array:2 [
          "identificador" => "sec0045"
          "titulo" => "Conflicts of interest"
        ]
        10 => array:2 [
          "identificador" => "xack781937"
          "titulo" => "Acknowledgments"
        ]
        11 => array:1 [
          "titulo" => "References"
        ]
      ]
    ]
    "pdfFichero" => "main.pdf"
    "tienePdf" => true
    "fechaRecibido" => "2023-10-09"
    "fechaAceptado" => "2024-02-06"
    "PalabrasClave" => array:2 [
      "en" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec1893690"
          "palabras" => array:4 [
            0 => "Psoriasis"
            1 => "Equity"
            2 => "Biological drugs"
            3 => "Spain"
          ]
        ]
      ]
      "es" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec1893691"
          "palabras" => array:4 [
            0 => "Psoriasis"
            1 => "Equidad"
            2 => "F&#225;rmacos biol&#243;gicos"
            3 => "Espa&#241;a"
          ]
        ]
      ]
    ]
    "tieneResumen" => true
    "resumen" => array:2 [
      "en" => array:2 [
        "titulo" => "Abstract"
        "resumen" => "<span id="abst0010" class="elsevierStyleSection elsevierViewall"><p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Spanish Autonomous Communities &#40;ACs&#41; are entitled to decide on the prescription requirements of their own territories&#44; which can create inequalities in access to new drugs in the management of psoriasis&#46; The objective of this study was to assess whether the level of restrictions in the access to new drugs for the management psoriasis was associated with the probability of achieving disease control measured using the Minimum Disease Activity &#40;MDA&#41; criteria&#46; Therefore&#44; we combined the results of 2 previous independent&#44; cross-sectional studies&#58; one that described the MDA in psoriasis by AC&#44; and another that evaluated the level of restrictions to drug access by AC&#46; We found that the higher the number of restrictions the lower the chances of achieving the MDA criteria &#40;<span class="elsevierStyleItalic">P</span>&#61;&#46;013&#41;&#46; Our results suggest that&#44; in Spain&#44; geographical differences in the access to new drugs may be creating health inequalities across the country&#46;</p></span>"
      ]
      "es" => array:2 [
        "titulo" => "Resumen"
        "resumen" => "<span id="abst0015" class="elsevierStyleSection elsevierViewall"><p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Las comunidades aut&#243;nomas &#40;CC&#46; AA&#46;&#41; espa&#241;olas deciden sobre las condiciones de prescripci&#243;n en su &#225;mbito territorial&#44; lo cual puede generar desigualdades en el acceso a nuevos f&#225;rmacos&#46; El objetivo del presente estudio fue evaluar la posible asociaci&#243;n entre el nivel de restricciones para acceder a nuevos f&#225;rmacos en psoriasis y la probabilidad de alcanzar el control de la enfermedad psori&#225;sica mediante la actividad m&#237;nima de la enfermedad &#40;AME&#41;&#46; Para ello se utilizaron los datos de dos estudios transversales independientes previos&#58; uno que describi&#243; la AME en Espa&#241;a&#44; y otro que evalu&#243; la cantidad de restricciones al acceso de f&#225;rmacos por CC&#46; AA&#46; Tanto en el modelo crudo como en el ajustado se observ&#243; que&#44; a mayor n&#250;mero de restricciones&#44; menor fue el porcentaje de pacientes en AME &#40;p<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;013&#41;&#46; Los resultados obtenidos son compatibles con una situaci&#243;n de inequidad en salud en Espa&#241;a que ser&#237;a preciso abordar&#46;</p></span>"
      ]
    ]
    "apendice" => array:1 [
      0 => array:1 [
        "seccion" => array:1 [
          0 => array:4 [
            "apendice" => "<p id="par0150" class="elsevierStylePara elsevierViewall"><elsevierMultimedia ident="upi0005"></elsevierMultimedia></p>"
            "etiqueta" => "Appendix B"
            "titulo" => "Supplementary data"
            "identificador" => "sec0055"
          ]
        ]
      ]
    ]
    "multimedia" => array:4 [
      0 => array:7 [
        "identificador" => "fig0005"
        "etiqueta" => "Figure 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr1.jpeg"
            "Alto" => 1042
            "Ancho" => 1343
            "Tamanyo" => 180670
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">Graphic representation of the level of restrictions in each autonomous community included in the study&#44; as well as the proportion of patients with well-controlled psoriatic disease &#40;measured according to minimal disease activity&#41;&#46;</p>"
        ]
      ]
      1 => array:8 [
        "identificador" => "tbl0005"
        "etiqueta" => "Table 1"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at1"
            "detalle" => "Table "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">ACs&#44; autonomous communities&#59; MDA&#44; minimal disease activity&#46;</p><p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">The level of regional restrictions considered was&#58; &#8220;Many in AC&#8221;&#58; regional restrictions greater than the therapeutic positioning index &#40;TPI&#41; for &#62;<span class="elsevierStyleHsp" style=""></span>50&#37; of the study drugs&#46; &#8220;Some in AC&#8221;&#58; regional restrictions greater than the TPI existing in <span class="elsevierStyleUnderline">&#60;</span><span class="elsevierStyleHsp" style=""></span>50&#37; of the study drugs&#46; &#8220;No restrictions in AC&#8221;&#58; no regional restrictions greater than the TPI for any drug&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " colspan="10" align="center" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Level of restrictions at AC and local level</th></tr><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " colspan="2" align="center" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">No AC restrictions &#40;local restrictions may exist though&#41;</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " colspan="2" align="center" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">No AC restrictions &#40;there are actual local restrictions&#41;</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " colspan="2" align="center" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">A few AC restrictions &#40;local restrictions may exist though&#41;</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " colspan="2" align="center" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Many AC restrictions &#40;local restrictions may exist though&#41;</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " colspan="2" align="center" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Many AC restrictions &#40;there are actual local restrictions&#41;</th></tr><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">N&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Percentage&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">N&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Percentage&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">N&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Percentage&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">N&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Percentage&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">N&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Percentage&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="11" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleBold">Characteristics of the sample</span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">No&#46; of patients &#37;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">365&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">44&#46;2&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">150&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">18&#46;2&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">49&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">5&#46;9&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">145&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">17&#46;6&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">116&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">14&#46;1&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">No&#46; of ACs &#37;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">7 41&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#46;2&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">11&#46;8&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">5&#46;9&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">23&#46;5&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">17&#46;6&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="11" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">Sex</span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleHsp" style=""></span>Male&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">232&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">63&#46;7&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">81&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">4&#46;0&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">32&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">65&#46;3&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">79&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">54&#46;5&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">67&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">57&#46;8&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleHsp" style=""></span>Female&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">132&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">36&#46;3&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">69&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">6&#46;0&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">17&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">34&#46;7&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">66&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">45&#46;5&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">49&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">42&#46;2&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="11" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">Use of biological therapies</span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleHsp" style=""></span>No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">175&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">48&#46;1&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">76&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">50&#46;7&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">29&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">59&#46;2&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">81&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">55&#46;9&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">54&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">47&#46;0&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleHsp" style=""></span>Yes&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">189&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">51&#46;9&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">74&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">49&#46;3&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">20&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">40&#46;8&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">64&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">44&#46;1&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">61&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">53&#46;0&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="11" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">Meets MDA</span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleHsp" style=""></span>No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">180&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">49&#46;3&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">94&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">62&#46;7&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">33&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">67&#46;3&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">99&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">68&#46;3&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">83&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">71&#46;6&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleHsp" style=""></span>Yes&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">185&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">50&#46;7&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">56&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">37&#46;3&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">16&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">32&#46;7&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">46&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">31&#46;7&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">33&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">28&#46;4&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="11" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">PASI &#60;</span><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">1 when completing the MDA questionnaire</span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleHsp" style=""></span>No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">216&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">59&#46;5&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">95&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">63&#46;8&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">38&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">77&#46;6&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">104&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">72&#46;2&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">69&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">59&#46;5&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleHsp" style=""></span>Yes&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">147&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">40&#46;5&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">54&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">36&#46;2&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">11&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">22&#46;4&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">40&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">27&#46;8&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">47&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">40&#46;5&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleHsp" style=""></span>Age &#40;in years&#41; mean &#40;standard deviation&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">51&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#40;14&#46;6&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">51&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#40;13&#46;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">54&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#40;15&#46;6&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">50&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#40;14&#46;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">52&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#40;13&#46;6&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab3689685.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">General characteristics of the sample of patients included in the study and groups created after categorizing them based on the level of restrictions in their corresponding autonomous communities &#40;ACs&#41;&#46;</p>"
        ]
      ]
      2 => array:5 [
        "identificador" => "upi0005"
        "tipo" => "MULTIMEDIAECOMPONENTE"
        "mostrarFloat" => false
        "mostrarDisplay" => true
        "Ecomponente" => array:2 [
          "fichero" => "mmc1.doc"
          "ficheroTamanyo" => 40448
        ]
      ]
      3 => array:5 [
        "identificador" => "fig0010"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => false
        "mostrarDisplay" => true
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "fx1.jpeg"
            "Alto" => 886
            "Ancho" => 1385
            "Tamanyo" => 161205
          ]
        ]
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "References"
      "seccion" => array:1 [
        0 => array:2 [
          "identificador" => "bibs0015"
          "bibliografiaReferencia" => array:9 [
            0 => array:3 [
              "identificador" => "bib0050"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Systemic pharmacological treatments for chronic plaque psoriasis&#58; A network meta-analysis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "E&#46; Sbidian"
                            1 => "A&#46; Chaimani"
                            2 => "I&#46; Garcia-Doval"
                            3 => "L&#46; Doney"
                            4 => "C&#46; Dressler"
                            5 => "C&#46; Hua"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1002/14651858.CD011535.pub6"
                      "Revista" => array:5 [
                        "tituloSerie" => "Cochrane database Syst Rev"
                        "fecha" => "2023"
                        "volumen" => "7"
                        "paginaInicial" => "CD011535"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/37436070"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib0055"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Practical update of the Recommendations Published by the Psoriasis Group of the Spanish Academy of Dermatology and Venereology &#40;GPS&#41; on the Treatment of Psoriasis with Biologic Therapy Part 1&#46; Concepts and General Management of Psoriasis with Biologic T &#91;Article in English&#44; Spanish&#93;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "J&#46;M&#46; Carrascosa"
                            1 => "L&#46; Puig"
                            2 => "I&#46; Belinch&#243;n Romero"
                            3 => "L&#46; Salgado-Boquete"
                            4 => "E&#46; del Alc&#225;zar"
                            5 => "J&#46;J&#46; Andr&#233;s Lencina"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.ad.2021.10.003"
                      "Revista" => array:6 [
                        "tituloSerie" => "Actas Dermosifiliogr"
                        "fecha" => "2022"
                        "volumen" => "113"
                        "paginaInicial" => "261"
                        "paginaFinal" => "277"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/35526919"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib0060"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "Ministerio de Sanidad del Gobierno de Espa&#241;a&#46; Documento informativo sobre la financiaci&#243;n y fijaci&#243;n de precio de los medicamentos en Espa&#241;a &#91;accessed 21 Jun 2022&#93; Available from&#58; <a target="_blank" href="https://www.sanidad.gob.es/profesionales/farmacia/pdf/20220526_Doc_Infor_Financiacion_Med_Esp.pdf">https&#58;&#47;&#47;www&#46;sanidad&#46;gob&#46;es&#47;profesionales&#47;farmacia&#47;pdf&#47;20220526&#95;Doc&#95;Infor&#95;Financiacion&#95;Med&#95;Esp&#46;pdf</a>"
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib0065"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Treatment Appraisal Reports&#58; Usefulness and Transparency"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "L&#46; Puig"
                            1 => "J&#46;M&#46; Carrascosa"
                            2 => "J&#46; Notario"
                            3 => "I&#46; Belinch&#243;n"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.ad.2019.04.006"
                      "Revista" => array:5 [
                        "tituloSerie" => "Actas Dermosifiliogr"
                        "fecha" => "2020"
                        "volumen" => "111"
                        "paginaInicial" => "3"
                        "paginaFinal" => "6"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib0070"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "S&#225;nchez-D&#237;az M&#44; Fl&#243;rez &#193;&#44; Ara-Mart&#237;n M&#44; Arias-Santiago S&#44; Botella-Estrada R&#44; Ca&#241;ueto J&#44; et al&#46; Condicionantes de acceso a nuevos medicamentos dermatol&#243;gicos en Espa&#241;a&#58; resultados del proyecto EQUIDAD&#46; Actas Dermosifiliogr&#46; doi&#58;10&#46;1016&#47;j&#46;ad&#46;2023&#46;10&#46;016&#46;"
                ]
              ]
            ]
            5 => array:3 [
              "identificador" => "bib0075"
              "etiqueta" => "6"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Definition of minimal disease activity in psoriasis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "G&#46; Carretero"
                            1 => "J&#46;M&#46; Carrascosa"
                            2 => "L&#46; Puig"
                            3 => "J&#46;L&#46; S&#225;nchez-Carazo"
                            4 => "A&#46; L&#243;pez-Ferrer"
                            5 => "P&#46; Cueva"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/jdv.16564"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Eur Acad Dermatol Venereol"
                        "fecha" => "2021"
                        "volumen" => "35"
                        "paginaInicial" => "422"
                        "paginaFinal" => "430"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32367536"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            6 => array:3 [
              "identificador" => "bib0080"
              "etiqueta" => "7"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Evaluating equality in psoriasis healthcare&#58; A cohort study of the impact of age on prescription of biologics"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "K&#46; Geale"
                            1 => "M&#46; Henriksson"
                            2 => "M&#46; Schmitt-Egenolf"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/bjd.14331"
                      "Revista" => array:6 [
                        "tituloSerie" => "Br J Dermatol"
                        "fecha" => "2016"
                        "volumen" => "174"
                        "paginaInicial" => "579"
                        "paginaFinal" => "587"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26616003"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            7 => array:3 [
              "identificador" => "bib0085"
              "etiqueta" => "8"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Inequalities in access to biological treatments for psoriasis&#58; Results from the Italian Psocare registry"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "L&#46; Naldi"
                            1 => "S&#46; Cazzaniga"
                            2 => "M&#46; di Mercurio"
                            3 => "E&#46; Grossi"
                            4 => "A&#46; Addis"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/bjd.15234"
                      "Revista" => array:6 [
                        "tituloSerie" => "Br J Dermatol"
                        "fecha" => "2017"
                        "volumen" => "176"
                        "paginaInicial" => "1331"
                        "paginaFinal" => "1338"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27973689"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            8 => array:3 [
              "identificador" => "bib0090"
              "etiqueta" => "9"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Access to psoriasis treatment in Brazil and Chile&#58; A cross-sectional multicentre Global Healthcare Study on Psoriasis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "J&#46;-T&#46; Maul"
                            1 => "F&#46; Fr&#246;hlich"
                            2 => "L&#46;V&#46; Maul"
                            3 => "R&#46; Stunnenberg"
                            4 => "F&#46; Valenzuela"
                            5 => "C&#46; de la Cruz"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1093/bjd/ljac128"
                      "Revista" => array:6 [
                        "tituloSerie" => "Br J Dermatol"
                        "fecha" => "2023"
                        "volumen" => "188"
                        "paginaInicial" => "533"
                        "paginaFinal" => "541"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/36653920"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
    "agradecimientos" => array:1 [
      0 => array:4 [
        "identificador" => "xack781937"
        "titulo" => "Acknowledgments"
        "texto" => "<p id="par0130" class="elsevierStylePara elsevierViewall">The MDA study has received financial support from Amirall and UCB laboratories&#46; The laboratories did not participate in the design of the study&#44; data analysis&#44; obtaining results&#44; or preparation of the publication manuscript&#46;</p><p id="par0135" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic">National coordinator&#58;</span>&#160;Gregorio Carretero Hern&#225;ndez&#46;</p><p id="par0140" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic">Regional coordinators&#58;</span>&#160;Mariano Ara Mart&#237;n&#44; Susana Armesto Alonso&#44; Isabel Belinch&#243;n Romero&#44; Noemi Eiris Salvado&#44; Marta Ferr&#225;n Farr&#233;s&#44; Cristina Galache Osuna&#44; Marta Garc&#237;a Bust&#237;nduy&#44; Javier Garc&#237;a Latasa de Aran&#237;bar&#44; Marc Juli&#225; Manresa&#44; Mar Llamas Velasco&#44; Anna L&#243;pez Ferrer&#44; M&#243;nica Roncero Riesco&#44; Diana Ruiz Genao&#44; Ricardo Ruiz-Villaverde&#44; Laura Salgado Boquete&#44; Caridad Soria Mart&#237;nez&#44; Eva Vilarrasa Rull&#46;&#160;Collaborating Dermatologists&#58;&#160;Mar&#237;a Teresa Abalde Pintos&#44; Alberto Alfaro Rubio&#44; Gloria Aparicio Espa&#241;ol&#44; Beatriz Aranegui Arteaga&#44; Ana Arechalde P&#233;rez&#44; Jorge Ar&#243;stegui Aguilar&#44; Itrziar Arrue Michelena&#44; Antoni Az&#243;n Masoliver&#44; Cristina Bajo del Pozo&#44; Adri&#225;n Ballano Ruiz&#44; Ofelia Baniandr&#233;s Rodr&#237;guez&#44; Susana Blanco Barios&#44; Mar&#237;a Teresa Bordel G&#243;mez&#44; Jos&#233; Manuel Carrascosa Carrillo&#44; Ana Mar&#237;a Carrizosa Esquivel&#44; Mar&#237;a Castellano Gonz&#225;lez&#44; Beatriz Castro Guti&#233;rrez&#44; Mar&#237;a Antonia Concell&#243;n Do&#241;ate&#44; Alberto Conde Taboada&#44; Raquel Conejero del Mazo&#44; Miriam Corral de la Calle&#44; Ra&#250;l Corbal&#225;n V&#233;lez&#44; Neus Curc&#243; Botargues&#44; Sonia de la Fuente Meira&#44; Cristina de las Heras&#44; Francisco de la Torre Gomar&#44; Elena del Alc&#225;zar Viladomi&#250;&#44; Rub&#233;n del R&#237;o Gil&#44; Carmen Delgado Mucientes&#44; Sonsoles Delgado Vicente&#44; Miguel Duarte Ferrera&#44; Carlos Dur&#225;n Vi&#225;n&#44; Pilar Escalonilla Garc&#237;a-Patos&#44; Jos&#233; Manuel Fern&#225;ndez Armenteros&#44; Mar&#237;a Luisa Fern&#225;ndez D&#237;az&#44; Cristina Fern&#225;ndez S&#225;nchez&#44; Mar&#237;a Victoria Fuentelsaz del Barrio&#44; Yolanda Fortu&#241;o Ru&#237;z&#44; Jos&#233; Fr&#237;as Iniesta&#44; Manuel Gal&#225;n Guti&#233;rrez&#44; Fernando Gallardo Hern&#225;ndez&#44; M&#243;nica Garc&#237;a Arpa&#44; Carmen Garc&#237;a Donoso&#44; Mar&#237;a Jos&#233; Garc&#237;a Fern&#225;ndez de Villalta&#44; Mercedes Garc&#237;a Font&#44; Miguel Garc&#237;a Gil&#44; Esther Garc&#237;a Mart&#237;nez&#44; Mar&#237;a Garc&#237;a S&#225;nchez&#44; Fernando Garc&#237;a Souto&#44; Cristina Garrido Colmenero&#44; Inma Gil Faure&#44; Mar&#237;a del Pino Gil Mateo&#44; Daniel Godoy D&#237;az&#44; Elena Godoy Gij&#243;n&#44; Pilar G&#243;mez Avivar&#44; Pilar G&#243;mez Centeno&#44; Celia G&#243;mez de Castro&#44; Santiago G&#243;mez D&#237;ez&#44; Borja G&#243;mez Vila&#44; &#193;lvaro Gonz&#225;lez Cantero&#44; Alicia Gonz&#225;lez Quesada&#44; Iris Gonz&#225;lez Villanueva&#44; Tamara Gracia Caza&#241;a&#44; Julia Paloma Hergueta S&#225;nchez&#44; Zaida Hern&#225;ndez Hern&#225;ndez&#44; Carlos Hern&#225;ndez Montoya&#44; Mercedes Hospital Gil&#44; Marina Lacalle Calder&#243;n&#44; Francisco Javier Laso Dosal&#44; Victoria Lezcano Biosca&#44; Angel L&#243;pez &#193;vila&#44; Daniel L&#243;pez Castillo&#44; Mar&#237;a L&#243;pez-Escobar Garc&#237;a-Prendes&#44; Jos&#233; Luis L&#243;pez Estebaranz&#44; Marta Lorda Esp&#233;s&#44; Dunia Luj&#225;n Rodr&#237;guez&#44; Laura Mahiques Santos&#44; Mar&#237;a Marcell&#225;n Fern&#225;ndez&#44; Juan M&#225;rquez Henr&#237;quez&#44; Laura Marqu&#233;s Mart&#237;n&#44; Servando Eugenio Marr&#243;n Moya&#44; Javier Mart&#237;n Alcalde&#44; Isabel Mart&#237;n Gonz&#225;lez&#44; Esther Mart&#237;n S&#225;ez&#44; I&#241;igo Mart&#237;nez de Espronceda Esquerro&#44; Ana Mart&#237;nez de Salinas Quintana&#44; Javier Mataix Mart&#237;nez&#44; Clara Matas Nadal&#44; Almudena Mateu Puchades&#44; Susana Medina Montalvo&#44; Ana Men&#233;ndez Garc&#237;a-Estrada&#44; Julia Miralles Botella&#44; Yosune Mitxelena Eceiza&#44; Jordi Mollet S&#225;nchez&#44; Juan Monte Serrano&#44; Andrea Montes Torres&#44; Ana Morales Callaghan&#44; Elisa Morales Larios&#44; Ana Luisa Morales Moya&#44; F&#225;tima Moreno Su&#225;rez&#44; Carlos Mu&#241;oz Santos&#44; Nuria No P&#233;rez&#44; Jaume Notario Rosa&#44; Nerea Ormaetxea P&#233;rez&#44; Laura Palacios Garc&#237;a&#44; Jos&#233; Pardo S&#225;nchez&#44; Silvia P&#233;rez Barrio&#44; Jos&#233; Antonio P&#233;rez Caballero&#44; Amalia P&#233;rez Gil&#44; Beatriz P&#233;rez Su&#225;rez&#44; Mar&#237;a Pestana Eliche&#44; Mar&#237;a Pousa Mart&#237;nez&#44; In&#233;s Poveda Montoyo&#44; Luc&#237;a Prieto Torres&#44; Laura Puebla Tornero&#44; Lluis Puig Sanz&#44; Josep Pujol Moncus&#237;&#44; Antonio Ram&#237;rez Andreo&#44; Jos&#233; Mar&#237;a Ram&#237;rez Concha&#44; Aquilina Ram&#237;rez Santos&#44; Leandra Reguero del Cura&#44; Sheila Requena L&#243;pez&#44; Miquel Ribera Pibernat&#44; Josep Riera Monroig&#44; Irene R&#237;o Garc&#237;a&#44; Raquel Rivera D&#237;az&#44; Ignacio Rivera Fuentes&#44; Vicen&#231; Rocamora Dur&#225;n&#44; Sabela Rodr&#237;guez Blanco&#44; Lourdes Rodr&#237;guez Freire&#44; Fernando Rodr&#237;guez Garc&#237;a&#44; Marina Rodr&#237;guez Mart&#237;n&#44; Isabel Rodr&#237;guez Nevado&#44; Guillermo Romero Aguilera&#44; Alberto Romero Mate&#44; Estrella Romero Sillero&#44; Jos&#233; Carlos Ruiz Carrascosa&#44; Javier Ruiz Mart&#237;nez&#44; Marc Sagrist&#225; Garc&#237;a&#44; Laura Sa&#237;nz Gaspar&#44; Ana Salas Mart&#237;nez&#44; Montserrat Salleras Redonet&#44; Prado S&#225;nchez Caminero&#44; Elena S&#225;nchez Largo&#44; Javier S&#225;nchez P&#233;rez&#44; Mar&#237;a Pilar S&#225;nchez Salas&#44; Jorge Santos-Juanes Jim&#233;nez&#44; Antonio Sahuquillo Torralba&#44; Agustina Segurado Rodr&#237;guez&#44; Miriam Sidr&#243; Sartos&#44; Ruth Solanas Trevi&#241;o&#44; Jos&#233; Su&#225;rez Hern&#225;ndez&#44; Rosa Taberner Ferrer&#44; Mar&#237;a Isabel &#218;beda Clemente&#44; Peru Urigoitia Ugalde&#44; Francisco V&#225;zquez L&#243;pez&#44; Diana Vel&#225;zquez Tarjuelo&#44; David Vidal Sarro&#44; Jaime Vilar Alejo&#44; Isabel Villegas Romero&#44; and Ignacio Yanguas Barona&#46; The EQUIDAD study has been promoted and funded by the Fundaci&#243;n Piel Sana AEDV&#46; Regional Coordinators of the ACs&#58;&#160;Mariano Ara Mart&#237;n&#44; Salvador Arias Santiago&#44; Rafael Botella Estrada&#44; Javier Ca&#241;ueto&#44; Gregorio Carretero Hern&#225;ndez&#44; Pablo Coto Segura&#44; Esther de Eusebio Murillo&#44; &#193;ngeles Fl&#243;rez&#44; Francisco Javier Garc&#237;a Latasa de Aran&#237;bar&#44; Vicente Garc&#237;a Patos Briones&#44; Jes&#250;s Gardeazabal Garc&#237;a&#44; Cristina G&#243;mez-Fern&#225;ndez&#44; Sergio Hern&#225;ndez Ostiz&#44; Rosa Izu Belloso&#44; &#193;ngel L&#243;pez &#193;vila&#44; Pilar Manchado L&#243;pez&#44; Ana Mart&#237;n-Santiago&#44; I&#241;igo Martinez De Espronceda Ezquerro&#44; Almudena Mateu Puchades&#44; Pedro Mercader Garc&#237;a&#44; Jaime Notario Rosa&#44; Luc&#237;a Palacio Aller&#44; Cristina P&#233;rez Hortet&#44; Luc&#237;a Quintana-Castanedo&#44; Raquel Rivera&#44; Vicen&#231; Rocamora Dur&#225;n&#44; Isabel M&#170; Rodr&#237;guez Nevado&#44; Ricardo Ruiz Villaverde&#44; Jos&#233; Su&#225;rez&#44; Lidia Trasobares Marug&#225;n&#44; Carmen Viz&#225;n de U&#241;a&#44; Ignacio Yanguas&#44; and Ander Zulaica-Garate&#46;</p>"
        "vista" => "all"
      ]
    ]
  ]
  "idiomaDefecto" => "en"
  "url" => "/00017310/0000011500000009/v2_202410160548/S0001731024006549/v2_202410160548/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "76882"
    "tipo" => "SECCION"
    "es" => array:2 [
      "titulo" => "Comunicaciones Breves"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "es"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/00017310/0000011500000009/v2_202410160548/S0001731024006549/v2_202410160548/en/main.pdf?idApp=UINPBA000044&text.app=https://actasdermo.org/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731024006549?idApp=UINPBA000044"
]
Share
Journal Information

Statistics

Follow this link to access the full text of the article

Brief Comunication
Study of the Impact of Restrictions on Access to Biological Drugs for the Management of Psoriasis on the Minimum Disease Activity Criteria: Subanalysis of AEDV EQUIDAD and AME Projects
Estudio del impacto de las restricciones en el acceso a fármacos biológicos en psoriasis sobre la actividad mínima de la enfermedad: subanálisis de los proyectos EQUIDAD y AME de la AEDV
M. Sánchez-Díaza,b, Á. Flórezc, G. Carretero-Hernándezd, M. Grau-Péreze,f, I. García-Dovalf,g,
Corresponding author
ignacio.garcia.doval@sergas.es

Corresponding author.
, J.M. Carrascosa-Carrilloh
a Unidad de Investigación, Fundación Piel Sana de la Academia Española de Dermatología y Venereología, Madrid, Spain
b Servicio de Dermatología, Hospital Universitario Virgen de las Nieves Instituto de Investigación Biosanitaria IBS, Granada, Spain
c Servicio de Dermatología, Complejo Hospitalario Universitario de Pontevedra, Grupo de Investigación DIPO, IIS Galicia Sur-SERGAS-UVIGO, Pontevedra, Spain
d Servicio de Dermatología, Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, Isla de Gran Canaria, Spain
e Servicio de Dermatología, Hospital Universitario Puerta de Hierro-Majadahonda, Majadahonda, Madrid, Spain
f Unidad de Investigación, Fundación Piel Sana de la Academia Española de Dermatología y Venereología, Madrid, Spain
g Servicio de Dermatología, Hospital do Meixoeiro, Vigo, Pontevedra, Spain
h Servicio de Dermatología, Hospital Universitario Germans Trias i Pujol, Badalona, Barcelona, Spain
Read
1189
Times
was read the article
234
Total PDF
955
Total HTML
Share statistics
 array:24 [
  "pii" => "S0001731024006549"
  "issn" => "00017310"
  "doi" => "10.1016/j.ad.2024.02.036"
  "estado" => "S300"
  "fechaPublicacion" => "2024-10-01"
  "aid" => "4048"
  "copyright" => "AEDV"
  "copyrightAnyo" => "2024"
  "documento" => "simple-article"
  "crossmark" => 1
  "subdocumento" => "crp"
  "cita" => "Actas Dermosifiliogr. 2024;115:T906-T911"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:1 [
    "total" => 0
  ]
  "itemSiguiente" => array:18 [
    "pii" => "S0001731024000425"
    "issn" => "00017310"
    "doi" => "10.1016/j.ad.2023.03.015"
    "estado" => "S300"
    "fechaPublicacion" => "2024-10-01"
    "aid" => "3804"
    "copyright" => "AEDV"
    "documento" => "simple-article"
    "crossmark" => 1
    "subdocumento" => "crp"
    "cita" => "Actas Dermosifiliogr. 2024;115:913-4"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:1 [
      "total" => 0
    ]
    "es" => array:11 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">CASOS PARA EL DIAGN&#211;STICO</span>"
      "titulo" => "N&#243;dulo eritematoso en labio superior"
      "tienePdf" => "es"
      "tieneTextoCompleto" => "es"
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "913"
          "paginaFinal" => "914"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "en" => array:1 [
          "titulo" => "Erythematous nodule on the upper lip"
        ]
      ]
      "contieneTextoCompleto" => array:1 [
        "es" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:7 [
          "identificador" => "fig0010"
          "etiqueta" => "Figura 2"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "gr2.jpeg"
              "Alto" => 621
              "Ancho" => 930
              "Tamanyo" => 215698
            ]
          ]
          "descripcion" => array:1 [
            "es" => "<p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Proliferaci&#243;n intrad&#233;rmica de estructuras vasculares lobuladas con endotelio prominente e infiltrado inflamatorio &#40;panor&#225;mica Hematoxilina&#38;Eosina&#41; &#40;A&#41;&#46; C&#233;lulas endoteliales prominentes con abundante citoplasma eosin&#243;filo &#40;H&#38;E x10&#41; &#40;B&#41;&#46; C&#233;lulas endoteliales prominentes con abundante citoplasma eosin&#243;filo rodeadas principalmente de linfocitos y algunos eosin&#243;filos aislados &#40;H&#38;E x20&#41; &#40;C&#41; Resoluci&#243;n completa de los n&#243;dulos eritematosos tras tratamiento con l&#225;ser&#46;</p>"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "M&#46;D&#46; Pegalajar-Garc&#237;a, I&#46; P&#233;rez-L&#243;pez, F&#46;J&#46; Navarro-Trivi&#241;o"
          "autores" => array:3 [
            0 => array:2 [
              "nombre" => "M&#46;D&#46;"
              "apellidos" => "Pegalajar-Garc&#237;a"
            ]
            1 => array:2 [
              "nombre" => "I&#46;"
              "apellidos" => "P&#233;rez-L&#243;pez"
            ]
            2 => array:2 [
              "nombre" => "F&#46;J&#46;"
              "apellidos" => "Navarro-Trivi&#241;o"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731024000425?idApp=UINPBA000044"
    "url" => "/00017310/0000011500000009/v2_202410160548/S0001731024000425/v2_202410160548/es/main.assets"
  ]
  "itemAnterior" => array:18 [
    "pii" => "S0001731024004150"
    "issn" => "00017310"
    "doi" => "10.1016/j.ad.2024.02.033"
    "estado" => "S300"
    "fechaPublicacion" => "2024-10-01"
    "aid" => "3955"
    "copyright" => "AEDV"
    "documento" => "simple-article"
    "crossmark" => 1
    "subdocumento" => "crp"
    "cita" => "Actas Dermosifiliogr. 2024;115:906-11"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:1 [
      "total" => 0
    ]
    "es" => array:14 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Comunicaci&#243;n Breve</span>"
      "titulo" => "Estudio del impacto de las restricciones en el acceso a f&#225;rmacos biol&#243;gicos en psoriasis sobre la actividad m&#237;nima de la enfermedad&#58; suban&#225;lisis de los proyectos EQUIDAD y AME de la AEDV"
      "tienePdf" => "es"
      "tieneTextoCompleto" => "es"
      "tieneResumen" => array:3 [
        0 => "es"
        1 => "es"
        2 => "en"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "906"
          "paginaFinal" => "911"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "en" => array:1 [
          "titulo" => "Study of the Impact of Restrictions on Access to Biological Drugs for the Management of Psoriasis on the Minimum Disease Activity Criteria&#58; Subanalysis of AEDV EQUIDAD and AME Projects"
        ]
      ]
      "contieneResumen" => array:2 [
        "es" => true
        "en" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "es" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 1
        "multimedia" => array:5 [
          "identificador" => "fig0010"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => false
          "mostrarDisplay" => true
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "fx1.jpeg"
              "Alto" => 886
              "Ancho" => 1340
              "Tamanyo" => 171271
            ]
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "M&#46; S&#225;nchez-D&#237;az, &#193;&#46; Fl&#243;rez, G&#46; Carretero-Hern&#225;ndez, M&#46; Grau-P&#233;rez, I&#46; Garc&#237;a-Doval, J&#46;M&#46; Carrascosa-Carrillo"
          "autores" => array:6 [
            0 => array:2 [
              "nombre" => "M&#46;"
              "apellidos" => "S&#225;nchez-D&#237;az"
            ]
            1 => array:2 [
              "nombre" => "&#193;&#46;"
              "apellidos" => "Fl&#243;rez"
            ]
            2 => array:2 [
              "nombre" => "G&#46;"
              "apellidos" => "Carretero-Hern&#225;ndez"
            ]
            3 => array:2 [
              "nombre" => "M&#46;"
              "apellidos" => "Grau-P&#233;rez"
            ]
            4 => array:2 [
              "nombre" => "I&#46;"
              "apellidos" => "Garc&#237;a-Doval"
            ]
            5 => array:2 [
              "nombre" => "J&#46;M&#46;"
              "apellidos" => "Carrascosa-Carrillo"
            ]
          ]
        ]
      ]
      "resumen" => array:1 [
        0 => array:3 [
          "titulo" => "Graphical abstract"
          "clase" => "graphical"
          "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall"><elsevierMultimedia ident="fig0010"></elsevierMultimedia></p></span>"
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731024004150?idApp=UINPBA000044"
    "url" => "/00017310/0000011500000009/v2_202410160548/S0001731024004150/v2_202410160548/es/main.assets"
  ]
  "asociados" => array:1 [
    0 => array:18 [
      "pii" => "S0001731024004150"
      "issn" => "00017310"
      "doi" => "10.1016/j.ad.2024.02.033"
      "estado" => "S300"
      "fechaPublicacion" => "2024-10-01"
      "aid" => "3955"
      "copyright" => "AEDV"
      "documento" => "simple-article"
      "crossmark" => 1
      "subdocumento" => "crp"
      "cita" => "Actas Dermosifiliogr. 2024;115:906-11"
      "abierto" => array:3 [
        "ES" => true
        "ES2" => true
        "LATM" => true
      ]
      "gratuito" => true
      "lecturas" => array:1 [
        "total" => 0
      ]
      "es" => array:14 [
        "idiomaDefecto" => true
        "cabecera" => "<span class="elsevierStyleTextfn">Comunicaci&#243;n Breve</span>"
        "titulo" => "Estudio del impacto de las restricciones en el acceso a f&#225;rmacos biol&#243;gicos en psoriasis sobre la actividad m&#237;nima de la enfermedad&#58; suban&#225;lisis de los proyectos EQUIDAD y AME de la AEDV"
        "tienePdf" => "es"
        "tieneTextoCompleto" => "es"
        "tieneResumen" => array:3 [
          0 => "es"
          1 => "es"
          2 => "en"
        ]
        "paginas" => array:1 [
          0 => array:2 [
            "paginaInicial" => "906"
            "paginaFinal" => "911"
          ]
        ]
        "titulosAlternativos" => array:1 [
          "en" => array:1 [
            "titulo" => "Study of the Impact of Restrictions on Access to Biological Drugs for the Management of Psoriasis on the Minimum Disease Activity Criteria&#58; Subanalysis of AEDV EQUIDAD and AME Projects"
          ]
        ]
        "contieneResumen" => array:2 [
          "es" => true
          "en" => true
        ]
        "contieneTextoCompleto" => array:1 [
          "es" => true
        ]
        "contienePdf" => array:1 [
          "es" => true
        ]
        "resumenGrafico" => array:2 [
          "original" => 1
          "multimedia" => array:5 [
            "identificador" => "fig0010"
            "tipo" => "MULTIMEDIAFIGURA"
            "mostrarFloat" => false
            "mostrarDisplay" => true
            "figura" => array:1 [
              0 => array:4 [
                "imagen" => "fx1.jpeg"
                "Alto" => 886
                "Ancho" => 1340
                "Tamanyo" => 171271
              ]
            ]
          ]
        ]
        "autores" => array:1 [
          0 => array:2 [
            "autoresLista" => "M&#46; S&#225;nchez-D&#237;az, &#193;&#46; Fl&#243;rez, G&#46; Carretero-Hern&#225;ndez, M&#46; Grau-P&#233;rez, I&#46; Garc&#237;a-Doval, J&#46;M&#46; Carrascosa-Carrillo"
            "autores" => array:6 [
              0 => array:2 [
                "nombre" => "M&#46;"
                "apellidos" => "S&#225;nchez-D&#237;az"
              ]
              1 => array:2 [
                "nombre" => "&#193;&#46;"
                "apellidos" => "Fl&#243;rez"
              ]
              2 => array:2 [
                "nombre" => "G&#46;"
                "apellidos" => "Carretero-Hern&#225;ndez"
              ]
              3 => array:2 [
                "nombre" => "M&#46;"
                "apellidos" => "Grau-P&#233;rez"
              ]
              4 => array:2 [
                "nombre" => "I&#46;"
                "apellidos" => "Garc&#237;a-Doval"
              ]
              5 => array:2 [
                "nombre" => "J&#46;M&#46;"
                "apellidos" => "Carrascosa-Carrillo"
              ]
            ]
          ]
        ]
        "resumen" => array:1 [
          0 => array:3 [
            "titulo" => "Graphical abstract"
            "clase" => "graphical"
            "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall"><elsevierMultimedia ident="fig0010"></elsevierMultimedia></p></span>"
          ]
        ]
      ]
      "idiomaDefecto" => "es"
      "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731024004150?idApp=UINPBA000044"
      "url" => "/00017310/0000011500000009/v2_202410160548/S0001731024004150/v2_202410160548/es/main.assets"
    ]
  ]
  "en" => array:21 [
    "idiomaDefecto" => true
    "cabecera" => "<span class="elsevierStyleTextfn">Brief Comunication</span>"
    "titulo" => " Study of the Impact of Restrictions on Access to Biological Drugs for the Management of Psoriasis on the Minimum Disease Activity Criteria&#58; Subanalysis of AEDV EQUIDAD and AME Projects"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "T906"
        "paginaFinal" => "T911"
      ]
    ]
    "autores" => array:1 [
      0 => array:4 [
        "autoresLista" => "M&#46; S&#225;nchez-D&#237;az, &#193;&#46; Fl&#243;rez, G&#46; Carretero-Hern&#225;ndez, M&#46; Grau-P&#233;rez, I&#46; Garc&#237;a-Doval, J&#46;M&#46; Carrascosa-Carrillo"
        "autores" => array:6 [
          0 => array:3 [
            "nombre" => "M&#46;"
            "apellidos" => "S&#225;nchez-D&#237;az"
            "referencia" => array:2 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
            ]
          ]
          1 => array:3 [
            "nombre" => "&#193;&#46;"
            "apellidos" => "Fl&#243;rez"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">c</span>"
                "identificador" => "aff0015"
              ]
            ]
          ]
          2 => array:3 [
            "nombre" => "G&#46;"
            "apellidos" => "Carretero-Hern&#225;ndez"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">d</span>"
                "identificador" => "aff0020"
              ]
            ]
          ]
          3 => array:3 [
            "nombre" => "M&#46;"
            "apellidos" => "Grau-P&#233;rez"
            "referencia" => array:2 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">e</span>"
                "identificador" => "aff0025"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">f</span>"
                "identificador" => "aff0030"
              ]
            ]
          ]
          4 => array:4 [
            "nombre" => "I&#46;"
            "apellidos" => "Garc&#237;a-Doval"
            "email" => array:1 [
              0 => "ignacio.garcia.doval@sergas.es"
            ]
            "referencia" => array:3 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">f</span>"
                "identificador" => "aff0030"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">g</span>"
                "identificador" => "aff0035"
              ]
              2 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">&#42;</span>"
                "identificador" => "cor0005"
              ]
            ]
          ]
          5 => array:3 [
            "nombre" => "J&#46;M&#46;"
            "apellidos" => "Carrascosa-Carrillo"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">h</span>"
                "identificador" => "aff0040"
              ]
            ]
          ]
        ]
        "afiliaciones" => array:8 [
          0 => array:3 [
            "entidad" => "Unidad de Investigaci&#243;n&#44; Fundaci&#243;n Piel Sana de la Academia Espa&#241;ola de Dermatolog&#237;a y Venereolog&#237;a&#44; Madrid&#44; Spain"
            "etiqueta" => "a"
            "identificador" => "aff0005"
          ]
          1 => array:3 [
            "entidad" => "Servicio de Dermatolog&#237;a&#44; Hospital Universitario Virgen de las Nieves Instituto de Investigaci&#243;n Biosanitaria IBS&#44; Granada&#44; Spain"
            "etiqueta" => "b"
            "identificador" => "aff0010"
          ]
          2 => array:3 [
            "entidad" => "Servicio de Dermatolog&#237;a&#44; Complejo Hospitalario Universitario de Pontevedra&#44; Grupo de Investigaci&#243;n DIPO&#44; IIS Galicia Sur-SERGAS-UVIGO&#44; Pontevedra&#44; Spain"
            "etiqueta" => "c"
            "identificador" => "aff0015"
          ]
          3 => array:3 [
            "entidad" => "Servicio de Dermatolog&#237;a&#44; Hospital Universitario de Gran Canaria Doctor Negr&#237;n&#44; Las Palmas de Gran Canaria&#44; Isla de Gran Canaria&#44; Spain"
            "etiqueta" => "d"
            "identificador" => "aff0020"
          ]
          4 => array:3 [
            "entidad" => "Servicio de Dermatolog&#237;a&#44; Hospital Universitario Puerta de Hierro-Majadahonda&#44; Majadahonda&#44; Madrid&#44; Spain"
            "etiqueta" => "e"
            "identificador" => "aff0025"
          ]
          5 => array:3 [
            "entidad" => "Unidad de Investigaci&#243;n&#44; Fundaci&#243;n Piel Sana de la Academia Espa&#241;ola de Dermatolog&#237;a y Venereolog&#237;a&#44; Madrid&#44; Spain"
            "etiqueta" => "f"
            "identificador" => "aff0030"
          ]
          6 => array:3 [
            "entidad" => "Servicio de Dermatolog&#237;a&#44; Hospital do Meixoeiro&#44; Vigo&#44; Pontevedra&#44; Spain"
            "etiqueta" => "g"
            "identificador" => "aff0035"
          ]
          7 => array:3 [
            "entidad" => "Servicio de Dermatolog&#237;a&#44; Hospital Universitario Germans Trias i Pujol&#44; Badalona&#44; Barcelona&#44; Spain"
            "etiqueta" => "h"
            "identificador" => "aff0040"
          ]
        ]
        "correspondencia" => array:1 [
          0 => array:3 [
            "identificador" => "cor0005"
            "etiqueta" => "&#8270;"
            "correspondencia" => "Corresponding author&#46;"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "es" => array:1 [
        "titulo" => "Estudio del impacto de las restricciones en el acceso a f&#225;rmacos biol&#243;gicos en psoriasis sobre la actividad m&#237;nima de la enfermedad&#58; suban&#225;lisis de los proyectos EQUIDAD y AME de la AEDV"
      ]
    ]
    "resumenGrafico" => array:2 [
      "original" => 1
      "multimedia" => array:5 [
        "identificador" => "fig0010"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => false
        "mostrarDisplay" => true
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "fx1.jpeg"
            "Alto" => 886
            "Ancho" => 1385
            "Tamanyo" => 161205
          ]
        ]
      ]
    ]
    "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0030">Introduction</span><p id="par0005" class="elsevierStylePara elsevierViewall">The development of biological drugs has represented a paradigm shift in the management of psoriasis&#44; allowing for long-term disease control with a good safety profile<a class="elsevierStyleCrossRefs" href="#bib0050"><span class="elsevierStyleSup">1&#44;2</span></a>&#46; However&#44; their use can have a significant economic impact on the Spanish National Health System<a class="elsevierStyleCrossRef" href="#bib0060"><span class="elsevierStyleSup">3</span></a> &#40;NHS&#41;&#46;</p><p id="par0010" class="elsevierStylePara elsevierViewall">Because of the specific characteristics of the Spanish NHS&#44; each autonomous community &#40;AC&#41; manages the health services of its territory and can decide on the conditions and requirements to prescribe drugs<a class="elsevierStyleCrossRefs" href="#bib0060"><span class="elsevierStyleSup">3&#44;4</span></a>&#46; In the cross-sectional EQUIDAD study&#44; a situation of disparities in the conditions of access to biological drugs for psoriasis among different ACs was observed&#44; with diversity in criteria at both regional and local levels&#46; The criteria did not appear to be based on decision-making methods that demonstrate the integration of scientific evidence<a class="elsevierStyleCrossRef" href="#bib0070"><span class="elsevierStyleSup">5</span></a>&#46;</p><p id="par0015" class="elsevierStylePara elsevierViewall">Independently&#44; the Spanish Academy of Dermatology and Venereology Psoriasis Working Group &#40;AEDV PWG&#41; developed the minimal disease activity &#40;MDA&#41; variable for the management of psoriasis<a class="elsevierStyleCrossRef" href="#bib0075"><span class="elsevierStyleSup">6</span></a>&#44; with the intent of using it as a measure of adequate disease management by characterizing patients with well-controlled psoriasis&#46; After it was defined&#44; a study was conducted at the end of 2022 to describe the situation of MDA&#44; evaluating the percentage of psoriatic patients who meet the MDA criteria in a routine clinical practice in Spain &#40;reference for MDA study&#41;&#46;</p><p id="par0020" class="elsevierStylePara elsevierViewall">The objective of the present study was to investigate the association between the probabilities of achieving MDA and the restrictions observed in access to new drugs in the treatment of psoriasis at both regional and local levels&#44; combining data from the independent EQUIDAD and MDA trials of the AEDV&#46;</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0035">Materials and methods</span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0040">Data source</span><p id="par0025" class="elsevierStylePara elsevierViewall">Data from 2 independent cross-sectional studies were combined&#58; the EQUIDAD<a class="elsevierStyleCrossRef" href="#bib0070"><span class="elsevierStyleSup">5</span></a> study conducted by the AEDV&#44; and the MDA &#40;reference&#41; study conducted by the AEDV PWG&#46; Briefly&#44; data for the EQUIDAD study were collected through an online questionnaire in March 2023&#44; which evaluated the existing regional and local prescription conditions in each AC from an ecological perspective&#46; The EQUIDAD study asked 2 dermatologists with management duties in each AC and only included restrictions reflected in official documents&#46; Data for the MDA study were collected from July through November 2022 via consecutive sampling of patients from psoriasis units from various geographic areas covering almost all provinces of Spain&#46;</p></span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0045">Drugs evaluated in the study</span><p id="par0030" class="elsevierStylePara elsevierViewall">New therapeutic targets for biological drugs for the treatment psoriasis were included&#44; for which funding resolutions were issued in the therapeutic positioning index &#40;TPI&#41; from 2016 through 2022 &#40;ixekizumab&#44; brodalumab&#44; guselkumab&#44; tildrakizumab&#44; risankizumab&#44; and bimekizumab&#41;&#46;</p></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0050">Variables of interest</span><p id="par0035" class="elsevierStylePara elsevierViewall">The following variables were collected&#58;<ul class="elsevierStyleList" id="lis0005"><li class="elsevierStyleListItem" id="lsti0005"><span class="elsevierStyleLabel">a&#41;</span><p id="par0040" class="elsevierStylePara elsevierViewall">Compliance with MDA&#58; MDA was defined as the absence of active arthritis plus 3 of the following 6 characteristics&#58; itch &#8804; 1&#47;10&#59; scaling &#8804; 2&#47;10&#59; redness &#8804; 2&#47;10&#59; visibility &#8804; 2&#47;10&#59; body surface area affected &#8804; 2&#37;&#59; Dermatology Life Quality Index &#40;DLQI&#41; scores &#8804; 2&#59; and absence of lesions in special locations<a class="elsevierStyleCrossRef" href="#bib0075"><span class="elsevierStyleSup">6</span></a>&#46;</p></li><li class="elsevierStyleListItem" id="lsti0010"><span class="elsevierStyleLabel">b&#41;</span><p id="par0045" class="elsevierStylePara elsevierViewall">Conditions for prescription in each AC&#58; For patients in each AC&#44; the level of restrictions greater than those required by the TPI at both regional and local levels for the prescription of the evaluated drugs was categorically recorded&#46;</p></li><li class="elsevierStyleListItem" id="lsti0015"><span class="elsevierStyleLabel">c&#41;</span><p id="par0050" class="elsevierStylePara elsevierViewall">Other variables&#58; Other variables from the MDA study were collected for each patient&#44; such as sex&#44; age&#44; use of biological drugs&#44; and AC of the treating hospital&#46;</p></li></ul></p></span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0055">Statistical analysis</span><p id="par0055" class="elsevierStylePara elsevierViewall">Qualitative variables were expressed as distributions of relative and absolute frequencies&#46; Quantitative variables were expressed as mean and standard deviation&#46; The probability of meeting the MDA criteria based on the level of regional and local restrictions described for each AC was analyzed using a crude multilevel logistic regression model&#44; along with yet another model adjusted for possible confounders such as age&#44; sex&#44; or current use of biological drugs&#46; A total of 3 sensitivity analyses were performed by regrouping the &#8220;level of restrictions&#8221; variable into different categories&#44; which eventually led to a dichotomous model &#40;less restrictive vs more restrictive ACs&#41;&#46; Statistical significance was considered for p-values &#60;<span class="elsevierStyleHsp" style=""></span>0&#46;05&#46; All analyses were performed with STATA&#174; &#40;Stata Corp&#46; 2021&#46; Stata Statistical Software&#58; version 17&#41;&#46;</p></span></span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0060">Results</span><p id="par0060" class="elsevierStylePara elsevierViewall">In the MDA study&#44; a final sample of 830 patients was obtained&#44; although only 825 were considered for this work&#44; representing a total of 17 different ACs &#40;5 patients did not have their region on record&#41;&#46; The mean age was 51&#46;4 years &#40;SD&#44; 14&#46;2&#41; and 49&#46;6&#37; were on biological therapy&#46; The MDA criteria were met in 40&#46;8&#37; of the patients included in the study&#46; A total of 62&#46;4&#37; of patients are still being followed in 9 ACs without regional restrictions &#40;although local restrictions may exist&#41;&#46; Combining the MDA data with the levels of restrictions in the ACs based on the EQUIDAD study<a class="elsevierStyleCrossRef" href="#bib0070"><span class="elsevierStyleSup">5</span></a>&#44; a trend can be seen&#44; with 28&#46;4&#37; of patients with MDA in the 3 most restrictive ACs vs 50&#46;7&#37; of MDA in the 7 least restrictive ACs&#44; with statistically significant differences &#40;p &#60;<span class="elsevierStyleHsp" style=""></span>0&#46;001&#41; &#40;<a class="elsevierStyleCrossRef" href="#fig0005">fig&#46; 1</a>&#41;&#46; The distribution of patients in the different AC groups based on the level of restrictions&#44; as well as the characteristics of these groups are shown in <a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>&#46;</p><elsevierMultimedia ident="fig0005"></elsevierMultimedia><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><p id="par0065" class="elsevierStylePara elsevierViewall">In the crude multilevel logistic model &#40;<a class="elsevierStyleCrossRef" href="#sec0050">Supplementary data Table 1</a>&#41;&#44; this gradient of probability of achieving MDA was replicated at the same time the level of restrictions decreased&#46; Being treated in an AC without regional restrictions &#40;although local ones may exist&#41; was independently associated with a higher probability of meeting the MDA criteria &#40;OR&#44; 2&#46;39&#59; 95&#37;CI&#44; 1&#46;04-5&#46;51&#41;&#46; Although adjustment for the use of biological drugs &#40;<a class="elsevierStyleCrossRef" href="#sec0050">Supplementary data Table 1</a>&#44; adjusted model&#41; showed a clear association with achieving MDA &#40;OR&#44; 5&#46;86&#59; 95&#37;CI&#44; 4&#46;18-8&#46;23&#41;&#44; it did not eliminate the effect of geographical restrictions &#40;OR&#44; 2&#46;64&#59; 95&#37;CI&#44; 1&#46;08-6&#46;42&#41;&#46; The model that categorized restrictions ordinally also showed a gradient of probability of achieving MDA as the level of restrictions dropped &#40;OR&#44; 1&#46;27&#59; 95&#37;CI&#44; 1&#46;06-1&#46;52&#59; p<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#46;011&#41;&#46;</p><p id="par0070" class="elsevierStylePara elsevierViewall">As sensitivity analysis&#44; the variable with the level of restrictions was regrouped into fewer categories&#44; finding similar results in all cases &#40;data not shown&#41;&#46; The graphic representation of the percentage of MDA found in each AC and its level of restrictions is shown in <a class="elsevierStyleCrossRef" href="#fig0005">Figure 1</a>&#46;</p></span><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0065">Discussion</span><p id="par0075" class="elsevierStylePara elsevierViewall">The presence of fewer restrictions&#44; both local and regional&#44; in access to new drugs for psoriasis seems to be associated with a higher probability of meeting the MDA criteria and&#44; therefore&#44; achieving adequate control of psoriatic disease&#46; This association is independent of other factors&#44; such as age or sex&#44; and is maintained when including the use of biological drugs by the patient in the model&#46;</p><p id="par0080" class="elsevierStylePara elsevierViewall">The relationship found between controlling psoriatic disease and other factors such as the use of biological drugs or socio-economic level are factors already evaluated previously<a class="elsevierStyleCrossRefs" href="#bib0080"><span class="elsevierStyleSup">7&#44;8</span></a>&#46; However&#44; few studies have evaluated the impact of drug access-related restrictions on the control of psoriasis&#44; focusing on comparisons across different countries<a class="elsevierStyleCrossRef" href="#bib0090"><span class="elsevierStyleSup">9</span></a>&#46; The differences between ACs reported in this study are more relevant as they are differences within the same country where equitable health care for all patients is presumed&#46;</p><p id="par0085" class="elsevierStylePara elsevierViewall">It seems logical to think that the absence of specific restrictions could favor the prescription of drugs based on clinical needs&#44; without being conditioned by financial or organizational factors&#46; The fact that the relationship between restrictions and MDA is maintained when including the binary variable &#8220;biologicals&#8221; in the model raises the possibility that the ease of access to new drugs does not fully explain the better disease control in areas with fewer restrictions&#46; Therefore&#44; persistent differences could be due to reasons other than treatment with new drugs &#40;which are also associated with the number of restrictions&#41;&#44; or to the possibility of selecting specific new drugs that are more effective based on national or international recommendations<a class="elsevierStyleCrossRef" href="#bib0055"><span class="elsevierStyleSup">2</span></a>&#46;</p><p id="par0090" class="elsevierStylePara elsevierViewall">An alternative explanation is that access to a dermatologist may be easier in ACs with fewer restrictions&#44; finding a higher proportion of patients with milder psoriasis who would more likely meet MDA criteria&#46;</p><p id="par0095" class="elsevierStylePara elsevierViewall">The strength of this study is that it is based on data from independent studies conducted before generating the hypothesis&#44; which makes it unlikely that MDA measurements could be biased by the description of local restrictions&#46; As for the limitations&#44; the main one is that it is an ecological study&#44; meaning that data on limitations are collected at AC level and the patients in whom MDA was measured may not be the same as those who experienced limitations in drug use&#46; It is also possible that restrictions allow the total number of prescriptions in the AC to be higher and&#44; although the benefit for each patient is smaller&#44; the overall benefit for the population is higher&#46; On the other hand&#44; the use of consecutive sampling may not be equally representative of the population of psoriatic patients in all ACs&#46; Additionally&#44; evaluating restrictions from a regional perspective probably does not accurately reflect the specific restrictions existing at each hospital level&#46;</p><p id="par0100" class="elsevierStylePara elsevierViewall">In conclusion&#44; the observed findings suggest that there is a relationship between a lower level of restrictions on access to biological drugs and a higher probability of adequate control of psoriatic disease&#46; It would be desirable to homogenize the prescription criteria among the different Spanish ACs to promote greater equity in the treatment of psoriasis nationwide</p></span><span id="sec0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0070">Conflicts of interest</span><p id="par0105" class="elsevierStylePara elsevierViewall">Manuel S&#225;nchez D&#237;az has received funding for attending conferences from Sanofi&#44; Lilly&#44; Novartis&#44; and Almirall&#46;</p><p id="par0110" class="elsevierStylePara elsevierViewall">&#193;ngeles Fl&#243;rez has received fees and&#47;or support for educational activities and&#47;or acted as a speaker and&#47;or consultant and&#47;or conducted clinical trials and&#47;or research projects for Abbvie&#44; ACELYRIN Inc&#44; Alcedis GmbH&#44; Almirall&#44; Amgen&#44; BMS&#44; Celgene&#44; Galderma&#44; Incyte Corporation&#44; Janssen-Cilag&#44; Kyowa Kirin&#44; Leo Pharma&#44; Lilly&#44; Novartis&#44; Pfizer&#44; Roche Farma&#44; Sanofi-Aventis&#44; Sun Pharma&#44; Takeda&#44; and UCB Biosciences GmbH&#46;</p><p id="par0115" class="elsevierStylePara elsevierViewall">Merc&#232; Grau-P&#233;rez has received funding for attending courses or conferences from Abbvie&#44; Almirall&#44; Janssen&#44; Lilly&#44; and Novartis&#46;</p><p id="par0120" class="elsevierStylePara elsevierViewall">Ignacio Garc&#237;a-Doval has received funding for attending conferences from Abbvie&#44; MSD&#44; Pfizer&#44; and Sanofi&#46;</p><p id="par0125" class="elsevierStylePara elsevierViewall">Jos&#233;-Manuel Carrascosa has received fees and&#47;or support for educational activities and&#47;or acted as a speaker and&#47;or consultant and&#47;or conducted clinical trials and&#47;or research projects for Abbvie&#44; Almirall&#44; Amgen&#44; BMS&#44; Celgene&#44; Galderma&#44; Janssen-Cilag&#44; Leo Pharma&#44; Lilly&#44; Novartis&#44; Pfizer&#44; Sanofi-Aventis&#44; UCB&#44; Sandoz&#44; and Boehringer Ingelheim&#46;</p></span></span>"
    "textoCompletoSecciones" => array:1 [
      "secciones" => array:12 [
        0 => array:3 [
          "identificador" => "xres2271948"
          "titulo" => "Graphical abstract"
          "secciones" => array:1 [
            0 => array:1 [
              "identificador" => "abst0005"
            ]
          ]
        ]
        1 => array:3 [
          "identificador" => "xres2271950"
          "titulo" => "Abstract"
          "secciones" => array:1 [
            0 => array:1 [
              "identificador" => "abst0010"
            ]
          ]
        ]
        2 => array:2 [
          "identificador" => "xpalclavsec1893690"
          "titulo" => "Keywords"
        ]
        3 => array:3 [
          "identificador" => "xres2271949"
          "titulo" => "Resumen"
          "secciones" => array:1 [
            0 => array:1 [
              "identificador" => "abst0015"
            ]
          ]
        ]
        4 => array:2 [
          "identificador" => "xpalclavsec1893691"
          "titulo" => "Palabras clave"
        ]
        5 => array:2 [
          "identificador" => "sec0005"
          "titulo" => "Introduction"
        ]
        6 => array:3 [
          "identificador" => "sec0010"
          "titulo" => "Materials and methods"
          "secciones" => array:4 [
            0 => array:2 [
              "identificador" => "sec0015"
              "titulo" => "Data source"
            ]
            1 => array:2 [
              "identificador" => "sec0020"
              "titulo" => "Drugs evaluated in the study"
            ]
            2 => array:2 [
              "identificador" => "sec0025"
              "titulo" => "Variables of interest"
            ]
            3 => array:2 [
              "identificador" => "sec0030"
              "titulo" => "Statistical analysis"
            ]
          ]
        ]
        7 => array:2 [
          "identificador" => "sec0035"
          "titulo" => "Results"
        ]
        8 => array:2 [
          "identificador" => "sec0040"
          "titulo" => "Discussion"
        ]
        9 => array:2 [
          "identificador" => "sec0045"
          "titulo" => "Conflicts of interest"
        ]
        10 => array:2 [
          "identificador" => "xack781937"
          "titulo" => "Acknowledgments"
        ]
        11 => array:1 [
          "titulo" => "References"
        ]
      ]
    ]
    "pdfFichero" => "main.pdf"
    "tienePdf" => true
    "fechaRecibido" => "2023-10-09"
    "fechaAceptado" => "2024-02-06"
    "PalabrasClave" => array:2 [
      "en" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec1893690"
          "palabras" => array:4 [
            0 => "Psoriasis"
            1 => "Equity"
            2 => "Biological drugs"
            3 => "Spain"
          ]
        ]
      ]
      "es" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec1893691"
          "palabras" => array:4 [
            0 => "Psoriasis"
            1 => "Equidad"
            2 => "F&#225;rmacos biol&#243;gicos"
            3 => "Espa&#241;a"
          ]
        ]
      ]
    ]
    "tieneResumen" => true
    "resumen" => array:2 [
      "en" => array:2 [
        "titulo" => "Abstract"
        "resumen" => "<span id="abst0010" class="elsevierStyleSection elsevierViewall"><p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Spanish Autonomous Communities &#40;ACs&#41; are entitled to decide on the prescription requirements of their own territories&#44; which can create inequalities in access to new drugs in the management of psoriasis&#46; The objective of this study was to assess whether the level of restrictions in the access to new drugs for the management psoriasis was associated with the probability of achieving disease control measured using the Minimum Disease Activity &#40;MDA&#41; criteria&#46; Therefore&#44; we combined the results of 2 previous independent&#44; cross-sectional studies&#58; one that described the MDA in psoriasis by AC&#44; and another that evaluated the level of restrictions to drug access by AC&#46; We found that the higher the number of restrictions the lower the chances of achieving the MDA criteria &#40;<span class="elsevierStyleItalic">P</span>&#61;&#46;013&#41;&#46; Our results suggest that&#44; in Spain&#44; geographical differences in the access to new drugs may be creating health inequalities across the country&#46;</p></span>"
      ]
      "es" => array:2 [
        "titulo" => "Resumen"
        "resumen" => "<span id="abst0015" class="elsevierStyleSection elsevierViewall"><p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Las comunidades aut&#243;nomas &#40;CC&#46; AA&#46;&#41; espa&#241;olas deciden sobre las condiciones de prescripci&#243;n en su &#225;mbito territorial&#44; lo cual puede generar desigualdades en el acceso a nuevos f&#225;rmacos&#46; El objetivo del presente estudio fue evaluar la posible asociaci&#243;n entre el nivel de restricciones para acceder a nuevos f&#225;rmacos en psoriasis y la probabilidad de alcanzar el control de la enfermedad psori&#225;sica mediante la actividad m&#237;nima de la enfermedad &#40;AME&#41;&#46; Para ello se utilizaron los datos de dos estudios transversales independientes previos&#58; uno que describi&#243; la AME en Espa&#241;a&#44; y otro que evalu&#243; la cantidad de restricciones al acceso de f&#225;rmacos por CC&#46; AA&#46; Tanto en el modelo crudo como en el ajustado se observ&#243; que&#44; a mayor n&#250;mero de restricciones&#44; menor fue el porcentaje de pacientes en AME &#40;p<span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>0&#44;013&#41;&#46; Los resultados obtenidos son compatibles con una situaci&#243;n de inequidad en salud en Espa&#241;a que ser&#237;a preciso abordar&#46;</p></span>"
      ]
    ]
    "apendice" => array:1 [
      0 => array:1 [
        "seccion" => array:1 [
          0 => array:4 [
            "apendice" => "<p id="par0150" class="elsevierStylePara elsevierViewall"><elsevierMultimedia ident="upi0005"></elsevierMultimedia></p>"
            "etiqueta" => "Appendix B"
            "titulo" => "Supplementary data"
            "identificador" => "sec0055"
          ]
        ]
      ]
    ]
    "multimedia" => array:4 [
      0 => array:7 [
        "identificador" => "fig0005"
        "etiqueta" => "Figure 1"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "gr1.jpeg"
            "Alto" => 1042
            "Ancho" => 1343
            "Tamanyo" => 180670
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">Graphic representation of the level of restrictions in each autonomous community included in the study&#44; as well as the proportion of patients with well-controlled psoriatic disease &#40;measured according to minimal disease activity&#41;&#46;</p>"
        ]
      ]
      1 => array:8 [
        "identificador" => "tbl0005"
        "etiqueta" => "Table 1"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at1"
            "detalle" => "Table "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">ACs&#44; autonomous communities&#59; MDA&#44; minimal disease activity&#46;</p><p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">The level of regional restrictions considered was&#58; &#8220;Many in AC&#8221;&#58; regional restrictions greater than the therapeutic positioning index &#40;TPI&#41; for &#62;<span class="elsevierStyleHsp" style=""></span>50&#37; of the study drugs&#46; &#8220;Some in AC&#8221;&#58; regional restrictions greater than the TPI existing in <span class="elsevierStyleUnderline">&#60;</span><span class="elsevierStyleHsp" style=""></span>50&#37; of the study drugs&#46; &#8220;No restrictions in AC&#8221;&#58; no regional restrictions greater than the TPI for any drug&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " colspan="10" align="center" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Level of restrictions at AC and local level</th></tr><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " colspan="2" align="center" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">No AC restrictions &#40;local restrictions may exist though&#41;</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " colspan="2" align="center" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">No AC restrictions &#40;there are actual local restrictions&#41;</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " colspan="2" align="center" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">A few AC restrictions &#40;local restrictions may exist though&#41;</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " colspan="2" align="center" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Many AC restrictions &#40;local restrictions may exist though&#41;</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " colspan="2" align="center" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Many AC restrictions &#40;there are actual local restrictions&#41;</th></tr><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">N&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Percentage&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">N&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Percentage&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">N&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Percentage&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">N&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Percentage&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">N&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Percentage&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="11" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleBold">Characteristics of the sample</span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">No&#46; of patients &#37;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">365&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">44&#46;2&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">150&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">18&#46;2&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">49&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">5&#46;9&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">145&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">17&#46;6&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">116&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">14&#46;1&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">No&#46; of ACs &#37;</span>&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">7 41&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#46;2&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">11&#46;8&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">5&#46;9&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">23&#46;5&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">17&#46;6&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="11" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">Sex</span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleHsp" style=""></span>Male&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">232&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">63&#46;7&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">81&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">4&#46;0&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">32&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">65&#46;3&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">79&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">54&#46;5&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">67&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">57&#46;8&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleHsp" style=""></span>Female&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">132&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">36&#46;3&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">69&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">6&#46;0&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">17&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">34&#46;7&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">66&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">45&#46;5&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">49&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">42&#46;2&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="11" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">Use of biological therapies</span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleHsp" style=""></span>No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">175&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">48&#46;1&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">76&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">50&#46;7&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">29&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">59&#46;2&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">81&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">55&#46;9&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">54&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">47&#46;0&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleHsp" style=""></span>Yes&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">189&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">51&#46;9&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">74&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">49&#46;3&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">20&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">40&#46;8&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">64&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">44&#46;1&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">61&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">53&#46;0&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="11" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">Meets MDA</span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleHsp" style=""></span>No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">180&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">49&#46;3&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">94&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">62&#46;7&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">33&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">67&#46;3&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">99&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">68&#46;3&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">83&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">71&#46;6&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleHsp" style=""></span>Yes&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">185&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">50&#46;7&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">56&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">37&#46;3&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">16&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">32&#46;7&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">46&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">31&#46;7&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">33&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">28&#46;4&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " colspan="11" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">PASI &#60;</span><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">1 when completing the MDA questionnaire</span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleHsp" style=""></span>No&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">216&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">59&#46;5&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">95&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">63&#46;8&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">38&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">77&#46;6&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">104&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">72&#46;2&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">69&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">59&#46;5&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleHsp" style=""></span>Yes&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">147&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">40&#46;5&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">54&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">36&#46;2&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">11&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">22&#46;4&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">40&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">27&#46;8&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">47&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">40&#46;5&#37;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleHsp" style=""></span>Age &#40;in years&#41; mean &#40;standard deviation&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">51&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#40;14&#46;6&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">51&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#40;13&#46;3&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">54&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#40;15&#46;6&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">50&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#40;14&#46;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">52&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#40;13&#46;6&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab3689685.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">General characteristics of the sample of patients included in the study and groups created after categorizing them based on the level of restrictions in their corresponding autonomous communities &#40;ACs&#41;&#46;</p>"
        ]
      ]
      2 => array:5 [
        "identificador" => "upi0005"
        "tipo" => "MULTIMEDIAECOMPONENTE"
        "mostrarFloat" => false
        "mostrarDisplay" => true
        "Ecomponente" => array:2 [
          "fichero" => "mmc1.doc"
          "ficheroTamanyo" => 40448
        ]
      ]
      3 => array:5 [
        "identificador" => "fig0010"
        "tipo" => "MULTIMEDIAFIGURA"
        "mostrarFloat" => false
        "mostrarDisplay" => true
        "figura" => array:1 [
          0 => array:4 [
            "imagen" => "fx1.jpeg"
            "Alto" => 886
            "Ancho" => 1385
            "Tamanyo" => 161205
          ]
        ]
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "References"
      "seccion" => array:1 [
        0 => array:2 [
          "identificador" => "bibs0015"
          "bibliografiaReferencia" => array:9 [
            0 => array:3 [
              "identificador" => "bib0050"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Systemic pharmacological treatments for chronic plaque psoriasis&#58; A network meta-analysis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "E&#46; Sbidian"
                            1 => "A&#46; Chaimani"
                            2 => "I&#46; Garcia-Doval"
                            3 => "L&#46; Doney"
                            4 => "C&#46; Dressler"
                            5 => "C&#46; Hua"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1002/14651858.CD011535.pub6"
                      "Revista" => array:5 [
                        "tituloSerie" => "Cochrane database Syst Rev"
                        "fecha" => "2023"
                        "volumen" => "7"
                        "paginaInicial" => "CD011535"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/37436070"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib0055"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Practical update of the Recommendations Published by the Psoriasis Group of the Spanish Academy of Dermatology and Venereology &#40;GPS&#41; on the Treatment of Psoriasis with Biologic Therapy Part 1&#46; Concepts and General Management of Psoriasis with Biologic T &#91;Article in English&#44; Spanish&#93;"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "J&#46;M&#46; Carrascosa"
                            1 => "L&#46; Puig"
                            2 => "I&#46; Belinch&#243;n Romero"
                            3 => "L&#46; Salgado-Boquete"
                            4 => "E&#46; del Alc&#225;zar"
                            5 => "J&#46;J&#46; Andr&#233;s Lencina"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.ad.2021.10.003"
                      "Revista" => array:6 [
                        "tituloSerie" => "Actas Dermosifiliogr"
                        "fecha" => "2022"
                        "volumen" => "113"
                        "paginaInicial" => "261"
                        "paginaFinal" => "277"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/35526919"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib0060"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "Ministerio de Sanidad del Gobierno de Espa&#241;a&#46; Documento informativo sobre la financiaci&#243;n y fijaci&#243;n de precio de los medicamentos en Espa&#241;a &#91;accessed 21 Jun 2022&#93; Available from&#58; <a target="_blank" href="https://www.sanidad.gob.es/profesionales/farmacia/pdf/20220526_Doc_Infor_Financiacion_Med_Esp.pdf">https&#58;&#47;&#47;www&#46;sanidad&#46;gob&#46;es&#47;profesionales&#47;farmacia&#47;pdf&#47;20220526&#95;Doc&#95;Infor&#95;Financiacion&#95;Med&#95;Esp&#46;pdf</a>"
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib0065"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Treatment Appraisal Reports&#58; Usefulness and Transparency"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "L&#46; Puig"
                            1 => "J&#46;M&#46; Carrascosa"
                            2 => "J&#46; Notario"
                            3 => "I&#46; Belinch&#243;n"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/j.ad.2019.04.006"
                      "Revista" => array:5 [
                        "tituloSerie" => "Actas Dermosifiliogr"
                        "fecha" => "2020"
                        "volumen" => "111"
                        "paginaInicial" => "3"
                        "paginaFinal" => "6"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib0070"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:1 [
                  "referenciaCompleta" => "S&#225;nchez-D&#237;az M&#44; Fl&#243;rez &#193;&#44; Ara-Mart&#237;n M&#44; Arias-Santiago S&#44; Botella-Estrada R&#44; Ca&#241;ueto J&#44; et al&#46; Condicionantes de acceso a nuevos medicamentos dermatol&#243;gicos en Espa&#241;a&#58; resultados del proyecto EQUIDAD&#46; Actas Dermosifiliogr&#46; doi&#58;10&#46;1016&#47;j&#46;ad&#46;2023&#46;10&#46;016&#46;"
                ]
              ]
            ]
            5 => array:3 [
              "identificador" => "bib0075"
              "etiqueta" => "6"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Definition of minimal disease activity in psoriasis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "G&#46; Carretero"
                            1 => "J&#46;M&#46; Carrascosa"
                            2 => "L&#46; Puig"
                            3 => "J&#46;L&#46; S&#225;nchez-Carazo"
                            4 => "A&#46; L&#243;pez-Ferrer"
                            5 => "P&#46; Cueva"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/jdv.16564"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Eur Acad Dermatol Venereol"
                        "fecha" => "2021"
                        "volumen" => "35"
                        "paginaInicial" => "422"
                        "paginaFinal" => "430"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32367536"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            6 => array:3 [
              "identificador" => "bib0080"
              "etiqueta" => "7"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Evaluating equality in psoriasis healthcare&#58; A cohort study of the impact of age on prescription of biologics"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "K&#46; Geale"
                            1 => "M&#46; Henriksson"
                            2 => "M&#46; Schmitt-Egenolf"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/bjd.14331"
                      "Revista" => array:6 [
                        "tituloSerie" => "Br J Dermatol"
                        "fecha" => "2016"
                        "volumen" => "174"
                        "paginaInicial" => "579"
                        "paginaFinal" => "587"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26616003"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            7 => array:3 [
              "identificador" => "bib0085"
              "etiqueta" => "8"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Inequalities in access to biological treatments for psoriasis&#58; Results from the Italian Psocare registry"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "L&#46; Naldi"
                            1 => "S&#46; Cazzaniga"
                            2 => "M&#46; di Mercurio"
                            3 => "E&#46; Grossi"
                            4 => "A&#46; Addis"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1111/bjd.15234"
                      "Revista" => array:6 [
                        "tituloSerie" => "Br J Dermatol"
                        "fecha" => "2017"
                        "volumen" => "176"
                        "paginaInicial" => "1331"
                        "paginaFinal" => "1338"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27973689"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            8 => array:3 [
              "identificador" => "bib0090"
              "etiqueta" => "9"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Access to psoriasis treatment in Brazil and Chile&#58; A cross-sectional multicentre Global Healthcare Study on Psoriasis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "J&#46;-T&#46; Maul"
                            1 => "F&#46; Fr&#246;hlich"
                            2 => "L&#46;V&#46; Maul"
                            3 => "R&#46; Stunnenberg"
                            4 => "F&#46; Valenzuela"
                            5 => "C&#46; de la Cruz"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1093/bjd/ljac128"
                      "Revista" => array:6 [
                        "tituloSerie" => "Br J Dermatol"
                        "fecha" => "2023"
                        "volumen" => "188"
                        "paginaInicial" => "533"
                        "paginaFinal" => "541"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/36653920"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
    "agradecimientos" => array:1 [
      0 => array:4 [
        "identificador" => "xack781937"
        "titulo" => "Acknowledgments"
        "texto" => "<p id="par0130" class="elsevierStylePara elsevierViewall">The MDA study has received financial support from Amirall and UCB laboratories&#46; The laboratories did not participate in the design of the study&#44; data analysis&#44; obtaining results&#44; or preparation of the publication manuscript&#46;</p><p id="par0135" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic">National coordinator&#58;</span>&#160;Gregorio Carretero Hern&#225;ndez&#46;</p><p id="par0140" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic">Regional coordinators&#58;</span>&#160;Mariano Ara Mart&#237;n&#44; Susana Armesto Alonso&#44; Isabel Belinch&#243;n Romero&#44; Noemi Eiris Salvado&#44; Marta Ferr&#225;n Farr&#233;s&#44; Cristina Galache Osuna&#44; Marta Garc&#237;a Bust&#237;nduy&#44; Javier Garc&#237;a Latasa de Aran&#237;bar&#44; Marc Juli&#225; Manresa&#44; Mar Llamas Velasco&#44; Anna L&#243;pez Ferrer&#44; M&#243;nica Roncero Riesco&#44; Diana Ruiz Genao&#44; Ricardo Ruiz-Villaverde&#44; Laura Salgado Boquete&#44; Caridad Soria Mart&#237;nez&#44; Eva Vilarrasa Rull&#46;&#160;Collaborating Dermatologists&#58;&#160;Mar&#237;a Teresa Abalde Pintos&#44; Alberto Alfaro Rubio&#44; Gloria Aparicio Espa&#241;ol&#44; Beatriz Aranegui Arteaga&#44; Ana Arechalde P&#233;rez&#44; Jorge Ar&#243;stegui Aguilar&#44; Itrziar Arrue Michelena&#44; Antoni Az&#243;n Masoliver&#44; Cristina Bajo del Pozo&#44; Adri&#225;n Ballano Ruiz&#44; Ofelia Baniandr&#233;s Rodr&#237;guez&#44; Susana Blanco Barios&#44; Mar&#237;a Teresa Bordel G&#243;mez&#44; Jos&#233; Manuel Carrascosa Carrillo&#44; Ana Mar&#237;a Carrizosa Esquivel&#44; Mar&#237;a Castellano Gonz&#225;lez&#44; Beatriz Castro Guti&#233;rrez&#44; Mar&#237;a Antonia Concell&#243;n Do&#241;ate&#44; Alberto Conde Taboada&#44; Raquel Conejero del Mazo&#44; Miriam Corral de la Calle&#44; Ra&#250;l Corbal&#225;n V&#233;lez&#44; Neus Curc&#243; Botargues&#44; Sonia de la Fuente Meira&#44; Cristina de las Heras&#44; Francisco de la Torre Gomar&#44; Elena del Alc&#225;zar Viladomi&#250;&#44; Rub&#233;n del R&#237;o Gil&#44; Carmen Delgado Mucientes&#44; Sonsoles Delgado Vicente&#44; Miguel Duarte Ferrera&#44; Carlos Dur&#225;n Vi&#225;n&#44; Pilar Escalonilla Garc&#237;a-Patos&#44; Jos&#233; Manuel Fern&#225;ndez Armenteros&#44; Mar&#237;a Luisa Fern&#225;ndez D&#237;az&#44; Cristina Fern&#225;ndez S&#225;nchez&#44; Mar&#237;a Victoria Fuentelsaz del Barrio&#44; Yolanda Fortu&#241;o Ru&#237;z&#44; Jos&#233; Fr&#237;as Iniesta&#44; Manuel Gal&#225;n Guti&#233;rrez&#44; Fernando Gallardo Hern&#225;ndez&#44; M&#243;nica Garc&#237;a Arpa&#44; Carmen Garc&#237;a Donoso&#44; Mar&#237;a Jos&#233; Garc&#237;a Fern&#225;ndez de Villalta&#44; Mercedes Garc&#237;a Font&#44; Miguel Garc&#237;a Gil&#44; Esther Garc&#237;a Mart&#237;nez&#44; Mar&#237;a Garc&#237;a S&#225;nchez&#44; Fernando Garc&#237;a Souto&#44; Cristina Garrido Colmenero&#44; Inma Gil Faure&#44; Mar&#237;a del Pino Gil Mateo&#44; Daniel Godoy D&#237;az&#44; Elena Godoy Gij&#243;n&#44; Pilar G&#243;mez Avivar&#44; Pilar G&#243;mez Centeno&#44; Celia G&#243;mez de Castro&#44; Santiago G&#243;mez D&#237;ez&#44; Borja G&#243;mez Vila&#44; &#193;lvaro Gonz&#225;lez Cantero&#44; Alicia Gonz&#225;lez Quesada&#44; Iris Gonz&#225;lez Villanueva&#44; Tamara Gracia Caza&#241;a&#44; Julia Paloma Hergueta S&#225;nchez&#44; Zaida Hern&#225;ndez Hern&#225;ndez&#44; Carlos Hern&#225;ndez Montoya&#44; Mercedes Hospital Gil&#44; Marina Lacalle Calder&#243;n&#44; Francisco Javier Laso Dosal&#44; Victoria Lezcano Biosca&#44; Angel L&#243;pez &#193;vila&#44; Daniel L&#243;pez Castillo&#44; Mar&#237;a L&#243;pez-Escobar Garc&#237;a-Prendes&#44; Jos&#233; Luis L&#243;pez Estebaranz&#44; Marta Lorda Esp&#233;s&#44; Dunia Luj&#225;n Rodr&#237;guez&#44; Laura Mahiques Santos&#44; Mar&#237;a Marcell&#225;n Fern&#225;ndez&#44; Juan M&#225;rquez Henr&#237;quez&#44; Laura Marqu&#233;s Mart&#237;n&#44; Servando Eugenio Marr&#243;n Moya&#44; Javier Mart&#237;n Alcalde&#44; Isabel Mart&#237;n Gonz&#225;lez&#44; Esther Mart&#237;n S&#225;ez&#44; I&#241;igo Mart&#237;nez de Espronceda Esquerro&#44; Ana Mart&#237;nez de Salinas Quintana&#44; Javier Mataix Mart&#237;nez&#44; Clara Matas Nadal&#44; Almudena Mateu Puchades&#44; Susana Medina Montalvo&#44; Ana Men&#233;ndez Garc&#237;a-Estrada&#44; Julia Miralles Botella&#44; Yosune Mitxelena Eceiza&#44; Jordi Mollet S&#225;nchez&#44; Juan Monte Serrano&#44; Andrea Montes Torres&#44; Ana Morales Callaghan&#44; Elisa Morales Larios&#44; Ana Luisa Morales Moya&#44; F&#225;tima Moreno Su&#225;rez&#44; Carlos Mu&#241;oz Santos&#44; Nuria No P&#233;rez&#44; Jaume Notario Rosa&#44; Nerea Ormaetxea P&#233;rez&#44; Laura Palacios Garc&#237;a&#44; Jos&#233; Pardo S&#225;nchez&#44; Silvia P&#233;rez Barrio&#44; Jos&#233; Antonio P&#233;rez Caballero&#44; Amalia P&#233;rez Gil&#44; Beatriz P&#233;rez Su&#225;rez&#44; Mar&#237;a Pestana Eliche&#44; Mar&#237;a Pousa Mart&#237;nez&#44; In&#233;s Poveda Montoyo&#44; Luc&#237;a Prieto Torres&#44; Laura Puebla Tornero&#44; Lluis Puig Sanz&#44; Josep Pujol Moncus&#237;&#44; Antonio Ram&#237;rez Andreo&#44; Jos&#233; Mar&#237;a Ram&#237;rez Concha&#44; Aquilina Ram&#237;rez Santos&#44; Leandra Reguero del Cura&#44; Sheila Requena L&#243;pez&#44; Miquel Ribera Pibernat&#44; Josep Riera Monroig&#44; Irene R&#237;o Garc&#237;a&#44; Raquel Rivera D&#237;az&#44; Ignacio Rivera Fuentes&#44; Vicen&#231; Rocamora Dur&#225;n&#44; Sabela Rodr&#237;guez Blanco&#44; Lourdes Rodr&#237;guez Freire&#44; Fernando Rodr&#237;guez Garc&#237;a&#44; Marina Rodr&#237;guez Mart&#237;n&#44; Isabel Rodr&#237;guez Nevado&#44; Guillermo Romero Aguilera&#44; Alberto Romero Mate&#44; Estrella Romero Sillero&#44; Jos&#233; Carlos Ruiz Carrascosa&#44; Javier Ruiz Mart&#237;nez&#44; Marc Sagrist&#225; Garc&#237;a&#44; Laura Sa&#237;nz Gaspar&#44; Ana Salas Mart&#237;nez&#44; Montserrat Salleras Redonet&#44; Prado S&#225;nchez Caminero&#44; Elena S&#225;nchez Largo&#44; Javier S&#225;nchez P&#233;rez&#44; Mar&#237;a Pilar S&#225;nchez Salas&#44; Jorge Santos-Juanes Jim&#233;nez&#44; Antonio Sahuquillo Torralba&#44; Agustina Segurado Rodr&#237;guez&#44; Miriam Sidr&#243; Sartos&#44; Ruth Solanas Trevi&#241;o&#44; Jos&#233; Su&#225;rez Hern&#225;ndez&#44; Rosa Taberner Ferrer&#44; Mar&#237;a Isabel &#218;beda Clemente&#44; Peru Urigoitia Ugalde&#44; Francisco V&#225;zquez L&#243;pez&#44; Diana Vel&#225;zquez Tarjuelo&#44; David Vidal Sarro&#44; Jaime Vilar Alejo&#44; Isabel Villegas Romero&#44; and Ignacio Yanguas Barona&#46; The EQUIDAD study has been promoted and funded by the Fundaci&#243;n Piel Sana AEDV&#46; Regional Coordinators of the ACs&#58;&#160;Mariano Ara Mart&#237;n&#44; Salvador Arias Santiago&#44; Rafael Botella Estrada&#44; Javier Ca&#241;ueto&#44; Gregorio Carretero Hern&#225;ndez&#44; Pablo Coto Segura&#44; Esther de Eusebio Murillo&#44; &#193;ngeles Fl&#243;rez&#44; Francisco Javier Garc&#237;a Latasa de Aran&#237;bar&#44; Vicente Garc&#237;a Patos Briones&#44; Jes&#250;s Gardeazabal Garc&#237;a&#44; Cristina G&#243;mez-Fern&#225;ndez&#44; Sergio Hern&#225;ndez Ostiz&#44; Rosa Izu Belloso&#44; &#193;ngel L&#243;pez &#193;vila&#44; Pilar Manchado L&#243;pez&#44; Ana Mart&#237;n-Santiago&#44; I&#241;igo Martinez De Espronceda Ezquerro&#44; Almudena Mateu Puchades&#44; Pedro Mercader Garc&#237;a&#44; Jaime Notario Rosa&#44; Luc&#237;a Palacio Aller&#44; Cristina P&#233;rez Hortet&#44; Luc&#237;a Quintana-Castanedo&#44; Raquel Rivera&#44; Vicen&#231; Rocamora Dur&#225;n&#44; Isabel M&#170; Rodr&#237;guez Nevado&#44; Ricardo Ruiz Villaverde&#44; Jos&#233; Su&#225;rez&#44; Lidia Trasobares Marug&#225;n&#44; Carmen Viz&#225;n de U&#241;a&#44; Ignacio Yanguas&#44; and Ander Zulaica-Garate&#46;</p>"
        "vista" => "all"
      ]
    ]
  ]
  "idiomaDefecto" => "en"
  "url" => "/00017310/0000011500000009/v2_202410160548/S0001731024006549/v2_202410160548/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "76882"
    "tipo" => "SECCION"
    "es" => array:2 [
      "titulo" => "Comunicaciones Breves"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "es"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/00017310/0000011500000009/v2_202410160548/S0001731024006549/v2_202410160548/en/main.pdf?idApp=UINPBA000044&text.app=https://actasdermo.org/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731024006549?idApp=UINPBA000044"
]
Article information
ISSN: 00017310
Original language: English
The statistics are updated each day
Year/Month Html Pdf Total
2024 November 18 3 21
2024 October 257 83 340
2024 September 223 54 277
2024 August 457 94 551

Follow this link to access the full text of the article

Idiomas
Actas Dermo-Sifiliográficas
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?